<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" xml:lang="EN">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">SMM</journal-id>
<journal-id journal-id-type="hwp">spsmm</journal-id>
<journal-id journal-id-type="nlm-ta">Stat Methods Med Res</journal-id>
<journal-title>Statistical Methods in Medical Research</journal-title>
<issn pub-type="ppub">0962-2802</issn>
<issn pub-type="epub">1477-0334</issn>
<publisher>
<publisher-name>SAGE Publications</publisher-name>
<publisher-loc>Sage UK: London, England</publisher-loc></publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1177/0962280211432220</article-id>
<article-id pub-id-type="publisher-id">10.1177_0962280211432220</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Articles</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Issues in performing a network meta-analysis</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" corresp="yes">
<name><surname>Senn</surname><given-names>Stephen</given-names></name>
<xref ref-type="aff" rid="aff1-0962280211432220">1</xref>
<xref ref-type="corresp" rid="corresp1-0962280211432220"/>
</contrib>
<contrib contrib-type="author">
<name><surname>Gavini</surname><given-names>Francois</given-names></name>
<xref ref-type="aff" rid="aff2-0962280211432220">2</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Magrez</surname><given-names>David</given-names></name>
<xref ref-type="aff" rid="aff2-0962280211432220">2</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Scheen</surname><given-names>André</given-names></name>
<xref ref-type="aff" rid="aff3-0962280211432220">3</xref>
</contrib>
<aff id="aff1-0962280211432220"><label>1</label>Competence Centre for Methodology and Statistics, CRP-Santé 1A rue Thomas Edison, L-1445 Strassen, Luxembourg</aff>
<aff id="aff2-0962280211432220"><label>2</label>I.R.I Servier, 50 rue Carnot 92284 Suresnes Cedex, France</aff>
<aff id="aff3-0962280211432220"><label>3</label>Division of Diabetes, Nutrition and Metabolic Disorders and Clinical Pharmacology Unit, University of Liège, CHU Liège, Sart Tilman (B25), B-4000 Liège, Belgium</aff>
</contrib-group>
<contrib-group content-type="issue">
<contrib contrib-type="guest-editor">
<name><surname>Julious</surname><given-names>Steven A</given-names></name>
</contrib>
</contrib-group>
<author-notes>
<corresp id="corresp1-0962280211432220">Stephen Senn, Competence Centre for Methodology and Statistics, CRP-Santé 1A rue Thomas Edison, L-1445 Strassen, Luxembourg. Email: <email>stephen.senn@crp-sante.lu</email></corresp>
</author-notes>
<pub-date pub-type="epub-ppub">
<month>4</month>
<year>2013</year>
</pub-date>
<volume>22</volume>
<issue>2</issue>
<issue-title>Special Issue: Meta analysis in Clinical Research</issue-title>
<fpage>169</fpage>
<lpage>189</lpage>
<permissions>
<copyright-statement>© The Author(s) 2011 Reprints and permissions: sagepub.co.uk/journalsPermissions.nav</copyright-statement>
<copyright-year>2011</copyright-year>
<copyright-holder content-type="sage">SAGE Publications</copyright-holder>
</permissions>
<abstract>
<p>The example of the analysis of a collection of trials in diabetes consisting of a sparsely connected network of 10 treatments is used to make some points about approaches to analysis. In particular various graphical and tabular presentations, both of the network and of the results are provided and the connection to the literature of incomplete blocks is made. It is clear from this example that is inappropriate to treat the main effect of trial as random and the implications of this for analysis are discussed. It is also argued that the generalisation from a classic random-effect meta-analysis to one applied to a network usually involves strong assumptions about the variance components involved. Despite this, it is concluded that such an analysis can be a useful way of exploring a set of trials.</p>
</abstract>
<kwd-group>
<kwd>Components of variance</kwd>
<kwd>incomplete blocks</kwd>
<kwd>indirect comparisons</kwd>
<kwd>mean-mean multiple comparisons plot</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<sec id="sec1-0962280211432220"><title>1 Introduction</title>
<p>In recent years, there has been rapidly increasing interest in network meta-analysis whether for the purpose of combining direct and indirect comparisons of a set of treatments to obtain pairwise comparisons<sup><xref ref-type="bibr" rid="bibr1-0962280211432220">1</xref>–<xref ref-type="bibr" rid="bibr10-0962280211432220">10</xref></sup> or the more specific purpose of determining how an experimental treatment in an active control equivalence study would have performed compared to placebo.<sup><xref ref-type="bibr" rid="bibr11-0962280211432220">11</xref>–<xref ref-type="bibr" rid="bibr14-0962280211432220">14</xref></sup> The problem can be described thus. We have a set of randomised controlled clinical studies that have been carried out investigating <inline-formula id="ilm1-0962280211432220"><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" display="inline" id="mml-math1-0962280211432220"><mml:mrow><mml:mi>t</mml:mi><mml:mo>&gt;</mml:mo><mml:mn>2</mml:mn></mml:mrow></mml:math></inline-formula> treatments in total. (It will hardly ever be the case that this is as part of some global programme but instead it will reflect decisions made at different times by different sets of investigators.) A typical study will have randomised patients to a subset of the <italic>t</italic> treatments and, in fact, in most cases will only have studied two of them. We now wish to make unbiased efficient estimates of all <inline-formula id="ilm2-0962280211432220"><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" display="inline" id="mml-math2-0962280211432220"><mml:mrow><mml:mi>t</mml:mi><mml:mrow><mml:mo/><mml:mo>(</mml:mo></mml:mrow><mml:mi>t</mml:mi><mml:mo>-</mml:mo><mml:mn>1</mml:mn><mml:mrow><mml:mo/><mml:mo>)</mml:mo></mml:mrow><mml:mo>/</mml:mo><mml:mn>2</mml:mn></mml:mrow></mml:math></inline-formula> possible pairwise treatment differences.</p>
<p>Put like this, the problem is very similar to a topic in experimental design with an extremely long pedigree, namely the analysis of incomplete block designs, whose development is particularly associated with the work of Frank Yates in the 1930s.<sup><xref ref-type="bibr" rid="bibr15-0962280211432220">15</xref>,<xref ref-type="bibr" rid="bibr16-0962280211432220">16</xref></sup> Indeed, the mathematical apparatus that can be used to perform a network meta-analysis is (or can be) very similar to that conventionally applied to incomplete block designs. (A particularly useful history of such designs is included in the book by Hinkelmann and Kempthorne<sup><xref ref-type="bibr" rid="bibr17-0962280211432220">17</xref></sup>.) Nevertheless, there are three important differences between the trials in a ‘network’ for a meta-analysis and the blocks in an incomplete blocks design. First, in an incomplete blocks design, it may often be the case that it has been possible to randomise treatments both within and between blocks whereas treatments are randomised only within trials in a ‘network’. This makes it difficult to justify a valid measurement of treatment effects at the two levels and hence to ‘recover inter-block information’ – a topic, which received an early treatment by Yates.<sup><xref ref-type="bibr" rid="bibr18-0962280211432220">18</xref></sup> Second, because the trials that have been performed will have been carried out by different investigators on different occasions using different protocols applied to differing populations it becomes plausible that the patient level variances will differ considerably from trial to trial. Finally, it is also plausible that the variation that may be seen in effects from trial to trial may be greater than might be predicted by within-trial variation.</p>
<p>In this article, we take the example of a recent network meta-analysis that we carried out in order to illustrate and critically discuss some problems that can arise. In particular, we propose various simple plots and tables that can aid in giving an impression of the nature of the data-set being summarised, in presenting and interpreting results and in identifying possible sources of difficulty. Two important issues that we consider, which are related to the discussion above are first, how should the main effect of trial be handled and second, what approach is appropriate to dealing with trial by treatment interaction. As regards the latter ‘effect’, one is, in fact confronted with a possible family of effects, as we shall explain in due course, and it may be more appropriate to refer to trial by treatments interactions in the plural.</p>
<p>The plan of the article is as follows. In Section 2 we describe a particular case study of a network meta-analysis in diabetes with which we were involved. We shall also present various graphical and tabular representations of the data-set that we consider useful. In Section 3 we shall present the frequentist statistical algorithms used to analyse the data. Section 4 presents the results and proposes various graphical representations, in Section 5 we explore some implications of heterogeneity and in Section 6 we consider how the approach used differs from Bayesian methods that are currently very popular. Finally in Section 7, we discuss advantages and limitations of network analysis and draw some conclusions.</p>
<p>The purpose of the article is didactic as regards approaches to meta-analysis. We hope that the mixture of techniques and graphs illustrated here, despite the fact that many are covered elsewhere in the literature, together with the data provided will prove useful to others wishing to explore this field. The results presented should <italic>not</italic> be taken as being a contribution to the literature evaluating the effects of treatment for diabetes. That would require, as a minimum, further investigation regarding some of the problems we illustrate.</p>
</sec>
<sec id="sec2-0962280211432220"><title>2 An example of a network meta-analysis in Diabetes</title>
<p>The objective of the network meta-analysis in Diabetes considered as example was to estimate the relative effects on HbA1c change, of adding different oral glucose-lowering agents to a baseline sulfonylurea therapy in patients with type 2 diabetes.</p>
<p>A systemic literature research for all relevant articles published from January 1993 to June 2009 was conducted in Medline and Embase. The search strategy was restricted to ‘randomised controlled trials’, ‘sulfonylurea or sulphonylurea’ and ‘humans’. This initial search was confirmed by combining each of the Medical Subject Headings key words ‘chlopropamide’, ‘glibenclamide’, ‘glyburide’, ‘gliclazide’, ‘glimepiride’, ‘glipizide’, ‘gliquidone’, ‘tolbutamide’ on the one hand and ‘RCT’ on the other hand. No language restriction was applied.</p>
<p>To determine the studies to be assessed further, two experts independently reviewed the abstract, titles or both sections of every record. Differences in opinion between reviewers were resolved by consensus, by referring back to the original data. In the case of missing information the official web sites of the pharmaceutical companies and of the FDA/EMA were checked in order to complete this information.</p>
<p>Patients with type 2 diabetes should have been treated with sulfonylurea monotherapy for at least 4 weeks before inclusion, whatever the sulfonylurea compound, provided that it was taken at at least half maximal recommended dose, with exclusion of patients treated with diet alone or with any other glucose-lowering agent (alone or in combination with sulfonylurea). All pharmacological compounds recognised by the World Health Organization as oral glucose-lowering agents were considered in the network meta-analysis: metformin, thiazolidinediones, alpha-glucosidase inhibitors, dipeptidyl peptidase-4 inhibitors and other oral blood glucose lowering drugs (glinides, benfluorex, etc.).</p>
<p>So, the trials were included in the analysis if they were open or double-blind randomised controlled trials (RCTs) with parallel groups, a minimum of 50 randomised patients and measurements of HbA1c after a follow-up ranging from 3 to 12 months.</p>
<p>Cross-over designs were excluded in case carry-over effects were a problem.</p>
<p>Where different dosages of the glucose-lowering agent added to baseline sulfonylurea therapy were tested in the clinical trial, only results obtained with the higher dosage used in the study were considered.</p>
<p>Initially the reviewers selected 31 studies but after data extraction and preparation for the analysis, this was reduced to 26 studies (6646 patients, 53 arms including one with 3 arms, 10 treatment groups) (<xref ref-type="fig" rid="fig1-0962280211432220">Figure 1</xref>). The 10 treatment groups were acarbose, benfluorex, metformin, miglitol, pioglitazone, placebo, rosiglitazone, sitagliptin, sulfonylurea alone and vildagliptin. (In various tables and figures that follow, the reader should note that <italic>SUalone</italic> is used to stand for <italic>sulfonylurea alone</italic> and the fact that such is the case implies that a placebo is <italic>not</italic> used and that the trial is open. Also in some tables the treatment name is shortened to the first four letters.)</p>
<p>The analysis considered a number of endpoints of which HbA1c was considered the most important. Since the purpose of this article is to illustrate various aspects of methodology rather than to make pronouncements about efficacy, we restrict presentation to this one measure only. The following data, if they were available, were extracted from the publications for each treatment arm of each study: number of patients, mean HbA1c baseline value, mean HbA1c value at outcome of the raw (unadjusted by baseline) value, mean HbA1c change from baseline and their corresponding standard deviation, standard error, 95% confidence interval.</p>
<p>To measure the treatment response per arm per study, the mean HbA1c change from baseline was used. Where this change was not available but the value at outcome of the raw (unadjusted by baseline) value was available, this was used instead. A consequence of this is that a general point that applies to clinical trials, namely that only differences between treatments have meaning, applies <italic>a fortiori</italic> here. Considering that, in a controlled clinical trial, the baselines values are expected to be equal between groups, unconditionally at least, treatment differences can be expected to be the same whether raw outcomes or change scores are used.</p>
<p>If the standard error and/or the confidence interval were available, the standard deviation was back-calculated from these. This gave up to three estimates of the standard deviation (including the one reported in the publication). Where more than one was available, the median of the available values was used. However, the individual values (which should only differ by rounding errors) were also examined for consistency.</p>
<p>Furthermore, an assumption of homoscedasticity within trials across arms (but not between trials) was assumed. The overall variances were calculated by weighting the variances for each arm by the degrees of freedom, as is standardly done for the two-sample <italic>t</italic>-test. Finally, by using the number of patients per arm <italic>n</italic> the variance of the mean for that arm was estimated by dividing the pooled variance estimate by <italic>n</italic>.</p>
<p><xref ref-type="table" rid="table1-0962280211432220">Table 1</xref> shows the set of trials and treatments available, with each row labeling the given study and each column giving the treatments included in that trial with a ‘1’ indicating not empty cells. The total in the final row of the table gives the number of times in the network as a whole that a particular treatment was studied and the final column gives the number of treatment arms included in a given trial. There were <inline-formula id="ilm3-0962280211432220"><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" display="inline" id="mml-math3-0962280211432220"><mml:mrow><mml:mn>26</mml:mn></mml:mrow></mml:math></inline-formula> studies in total and it can be seen that with the exception of the Willms study, which had three arms, all the studies had two arms so that in total there were <inline-formula id="ilm4-0962280211432220"><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" display="inline" id="mml-math4-0962280211432220"><mml:mrow><mml:mn>25</mml:mn><mml:mo>×</mml:mo><mml:mn>2</mml:mn><mml:mo>+</mml:mo><mml:mn>3</mml:mn><mml:mo>=</mml:mo><mml:mn>53</mml:mn></mml:mrow></mml:math></inline-formula> arms, with placebo being included <inline-formula id="ilm5-0962280211432220"><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" display="inline" id="mml-math5-0962280211432220"><mml:mrow><mml:mn>19</mml:mn></mml:mrow></mml:math></inline-formula> times and rosiglitazone <inline-formula id="ilm6-0962280211432220"><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" display="inline" id="mml-math6-0962280211432220"><mml:mrow><mml:mn>10</mml:mn></mml:mrow></mml:math></inline-formula> times.
<table-wrap id="table1-0962280211432220" position="float"><label>Table 1.</label><caption><p>Matrix showing the network of trials and treatments</p></caption>
<graphic alternate-form-of="table1-0962280211432220" xlink:href="10.1177_0962280211432220-table1.tif"/>
<table frame="hsides"><thead align="left">
<tr><th>Studies and treatments available</th>
</tr></thead>
<tbody align="left">
<tr><th>Treatment</th>
<th>acar</th>
<th>benf</th>
<th>metf</th>
<th>migl</th>
<th>piog</th>
<th>plac</th>
<th>rosi</th>
<th>sita</th>
<th>SUal</th>
<th>vild</th>
<th>Nobserved</th>
</tr>
<tr>
<td>Study</td>
</tr>
<tr>
<td>De Fronzo (1995)</td>
<td>1</td>
<td>1</td>
<td>2</td>
</tr>
<tr>
<td>Lewin (2007)</td>
<td>1</td>
<td>1</td>
<td>2</td>
</tr>
<tr>
<td>Willms (1999)</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>3</td>
</tr>
<tr>
<td>Davidson (2007)</td>
<td>1</td>
<td>1</td>
<td>2</td>
</tr>
<tr>
<td>Wolffenbuttel (1999)</td>
<td>1</td>
<td>1</td>
<td>2</td>
</tr>
<tr>
<td>Kipnes (2001)</td>
<td>1</td>
<td>1</td>
<td>2</td>
</tr>
<tr>
<td>Kerenyi (2004)</td>
<td>1</td>
<td>1</td>
<td>2</td>
</tr>
<tr>
<td>Hanefeld (2004)</td>
<td>1</td>
<td>1</td>
<td>2</td>
</tr>
<tr>
<td>Derosa (2004)</td>
<td>1</td>
<td>1</td>
<td>2</td>
</tr>
<tr>
<td>Baksi (2004)</td>
<td>1</td>
<td>1</td>
<td>2</td>
</tr>
<tr>
<td>Rosenstock (2008)</td>
<td>1</td>
<td>1</td>
<td>2</td>
</tr>
<tr>
<td>Zhu (2003)</td>
<td>1</td>
<td>1</td>
<td>2</td>
</tr>
<tr>
<td>Yang (2003)</td>
<td>1</td>
<td>1</td>
<td>2</td>
</tr>
<tr>
<td>Vongthavaravat (2002)</td>
<td>1</td>
<td>1</td>
<td>2</td>
</tr>
<tr>
<td>Oyama (2008)</td>
<td>1</td>
<td>1</td>
<td>2</td>
</tr>
<tr>
<td>Costa (1997)</td>
<td>1</td>
<td>1</td>
<td>2</td>
</tr>
<tr>
<td>Hermansen (2007)</td>
<td>1</td>
<td>1</td>
<td>2</td>
</tr>
<tr>
<td>Garber (2008)</td>
<td>1</td>
<td>1</td>
<td>2</td>
</tr>
<tr>
<td>Alex (1998)</td>
<td>1</td>
<td>1</td>
<td>2</td>
</tr>
<tr>
<td>Johnston (1994)</td>
<td>1</td>
<td>1</td>
<td>2</td>
</tr>
<tr>
<td>Johnston (1998a)</td>
<td>1</td>
<td>1</td>
<td>2</td>
</tr>
<tr>
<td>Kim (2007)</td>
<td>1</td>
<td>1</td>
<td>2</td>
</tr>
<tr>
<td>Johnston (1998b)</td>
<td>1</td>
<td>1</td>
<td>2</td>
</tr>
<tr>
<td>Gonzalez-Ortiz (2004)</td>
<td>1</td>
<td>1</td>
<td>2</td>
</tr>
<tr>
<td>Stucci (1996)</td>
<td>1</td>
<td>1</td>
<td>2</td>
</tr>
<tr>
<td>Moulin (2006)</td>
<td>1</td>
<td>1</td>
<td>2</td>
</tr>
<tr>
<td>Not observed</td>
<td>3</td>
<td>2</td>
<td>8</td>
<td>3</td>
<td>3</td>
<td>19</td>
<td>10</td>
<td>1</td>
<td>3</td>
<td>1</td>
<td>53</td>
</tr>
</tbody>
</table>
</table-wrap></p>
<p>An alternative summary of the data available is given in <xref ref-type="table" rid="table2-0962280211432220">Table 2</xref>, which gives the frequency with which particular pairs of treatments were studied. The off-diagonal elements give pair frequencies and the diagonal elements give the number of times the treatment appeared. Note that because one of the trials, Willms (1999), had three treatments, acarbose, metformin and placebo, for these three treatments the treatment total on the diagonal for these treatments is one less than would appear to be the case by studying the number of pairs involved.
<table-wrap id="table2-0962280211432220" position="float"><label>Table 2.</label><caption><p>Frequency with which particular treatment pairs were studied</p></caption>
<graphic alternate-form-of="table2-0962280211432220" xlink:href="10.1177_0962280211432220-table2.tif"/>
<table frame="hsides"><thead align="left">
<tr><th colspan="11">Frequency of treatment pairs</th>
</tr></thead>
<tbody align="left">
<tr>
<td>Treatment</td>
<td>acar</td>
<td>benf</td>
<td>metf</td>
<td>migl</td>
<td>piog</td>
<td>plac</td>
<td>rosi</td>
<td>sita</td>
<td>SUal</td>
<td>vild</td>
</tr>
<tr>
<td>Treatment</td>
</tr>
<tr>
<td>acar</td>
<td>3</td>
<td>1</td>
<td>2</td>
<td>1</td>
</tr>
<tr>
<td>benf</td>
<td>2</td>
<td>2</td>
</tr>
<tr>
<td>metf</td>
<td>1</td>
<td>8</td>
<td>1</td>
<td>4</td>
<td>2</td>
<td>1</td>
</tr>
<tr>
<td>migl</td>
<td>3</td>
<td>3</td>
</tr>
<tr>
<td>piog</td>
<td>1</td>
<td>3</td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td>plac</td>
<td>2</td>
<td>2</td>
<td>4</td>
<td>3</td>
<td>1</td>
<td>19</td>
<td>6</td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td>rosi</td>
<td>2</td>
<td>1</td>
<td>6</td>
<td>10</td>
<td>1</td>
</tr>
<tr>
<td>sita</td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td>SUal</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>3</td>
</tr>
<tr>
<td>vild</td>
<td>1</td>
<td>1</td>
</tr>
</tbody>
</table>
</table-wrap></p>
<p>A small point of presentation for both tables is that clarity is improved by replacing the number 0 by a blank. This makes it easier to see which pairs are not represented.</p>
<p>Tables <xref ref-type="table" rid="table1-0962280211432220">1</xref> and <xref ref-type="table" rid="table2-0962280211432220">2</xref> also allow one to describe the network and more especially, the different direct comparisons considered.</p>
<p>A further complication of the data is that in some trials change from baseline values were reported and in others unadjusted outcome values. This means that the end results are not comparable from trial to trial, although they are comparable <italic>within</italic> trials. Since, however, we have elected to treat the main effect of trial as fixed, all analyses are based on within-trial contrasts and the fact that some are formed from differences from baseline and some from raw outcomes does not matter.</p>
<p>The data that were used for analysis are provided in an Appendix so that readers may check our conclusions.</p>
</sec>
<sec id="sec3-0962280211432220"><title>3 Approaches to analysis</title>
<p>A suitable standard approach to analysing data that consists of various measurements made with different precision is to use the technique of generalised least squares (GLS), which leads to what is sometimes referred to as the Aitken estimator because of Aitken’s influential paper<sup><xref ref-type="bibr" rid="bibr19-0962280211432220">19</xref></sup> of 1934. (It is interesting to note that this appeared at a very similar time to Yates’s work on incomplete blocks.)</p>
<p>We suppose that we have a linear equation that may be expressed in matrix form as:
<disp-formula id="disp-formula1-0962280211432220"><label>(1)</label><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" display="inline" id="math1-0962280211432220"><mml:mrow><mml:mtext mathvariant="bold">Y</mml:mtext><mml:mo mathvariant="bold">=</mml:mo><mml:mtext mathvariant="bold">X</mml:mtext><mml:mo>β</mml:mo><mml:mo mathvariant="bold">+</mml:mo><mml:mo>ɛ</mml:mo><mml:mo mathvariant="bold">.</mml:mo></mml:mrow></mml:math><graphic alternate-form-of="disp-formula1-0962280211432220" xlink:href="10.1177_0962280211432220-eq1.tif"/></disp-formula>
</p>
<p>Here <bold>Y</bold> is an <inline-formula id="ilm7-0962280211432220"><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" display="inline" id="mml-math7-0962280211432220"><mml:mrow><mml:mi>n</mml:mi><mml:mo>×</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:math></inline-formula> vector of observations, <bold>X</bold> is an <inline-formula id="ilm8-0962280211432220"><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" display="inline" id="mml-math8-0962280211432220"><mml:mrow><mml:mi>n</mml:mi><mml:mo>×</mml:mo><mml:mi>p</mml:mi></mml:mrow></mml:math></inline-formula> matrix of predictors and <inline-formula id="ilm9-0962280211432220"><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" display="inline" id="mml-math9-0962280211432220"><mml:mrow><mml:mo>ɛ</mml:mo></mml:mrow></mml:math></inline-formula> an <inline-formula id="ilm10-0962280211432220"><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" display="inline" id="mml-math10-0962280211432220"><mml:mrow><mml:mi>n</mml:mi><mml:mo>×</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:math></inline-formula> vector of disturbance terms with <inline-formula id="ilm11-0962280211432220"><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" display="inline" id="mml-math11-0962280211432220"><mml:mrow><mml:mi>E</mml:mi><mml:mrow><mml:mo/><mml:mo>[</mml:mo></mml:mrow><mml:msub><mml:mrow><mml:mi>ɛ</mml:mi></mml:mrow><mml:mrow><mml:mi>i</mml:mi></mml:mrow></mml:msub><mml:mrow><mml:mo/><mml:mo>]</mml:mo></mml:mrow><mml:mo>=</mml:mo><mml:mn>0</mml:mn><mml:mrow><mml:mo/></mml:mrow><mml:mi>   </mml:mi><mml:mo>∀</mml:mo><mml:mi>i</mml:mi><mml:mrow><mml:mo/></mml:mrow><mml:mi>i</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn><mml:mo>,</mml:mo><mml:mo>…</mml:mo><mml:mo>,</mml:mo><mml:mi>n</mml:mi></mml:mrow></mml:math></inline-formula> and
<disp-formula id="disp-formula2-0962280211432220"><label>(2)</label><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" display="inline" id="math2-0962280211432220"><mml:mrow><mml:mi>E</mml:mi><mml:mrow><mml:mo/><mml:mo>[</mml:mo></mml:mrow><mml:mo>ɛɛ</mml:mo><mml:mo mathvariant="bold">'</mml:mo><mml:mrow><mml:mo/><mml:mo>]</mml:mo></mml:mrow><mml:mo mathvariant="bold">=</mml:mo><mml:mo>Σ</mml:mo><mml:mo mathvariant="bold">.</mml:mo></mml:mrow></mml:math><graphic alternate-form-of="disp-formula2-0962280211432220" xlink:href="10.1177_0962280211432220-eq2.tif"/></disp-formula>
</p>
<p>Here, <inline-formula id="ilm12-0962280211432220"><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" display="inline" id="mml-math12-0962280211432220"><mml:mrow><mml:mo>Σ</mml:mo></mml:mrow></mml:math></inline-formula> is the variance-covariance matrix for the disturbance terms, assumed known. The Aitken estimator is then given by:
<disp-formula id="disp-formula3-0962280211432220"><label>(3)</label><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" display="inline" id="math3-0962280211432220"><mml:mrow><mml:mover><mml:mrow><mml:mo>β</mml:mo></mml:mrow><mml:mi>∧</mml:mi></mml:mover><mml:mo mathvariant="bold">=</mml:mo><mml:mrow><mml:mo mathvariant="bold"/><mml:mo mathvariant="bold">(</mml:mo></mml:mrow><mml:msup><mml:mrow><mml:mtext mathvariant="bold">X</mml:mtext><mml:mo mathvariant="bold">'</mml:mo><mml:mo>Σ</mml:mo></mml:mrow><mml:mrow><mml:mo mathvariant="bold">-</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:msup><mml:mtext mathvariant="bold">X</mml:mtext><mml:msup><mml:mrow><mml:mo mathvariant="bold"/><mml:mo mathvariant="bold">)</mml:mo></mml:mrow><mml:mrow><mml:mo mathvariant="bold">-</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:msup><mml:msup><mml:mrow><mml:mi mathvariant="bold">X</mml:mi><mml:mo mathvariant="bold">'</mml:mo><mml:mo>Σ</mml:mo></mml:mrow><mml:mrow><mml:mo mathvariant="bold">-</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:msup><mml:mtext mathvariant="bold">Y</mml:mtext><mml:mo mathvariant="bold">.</mml:mo></mml:mrow></mml:math><graphic alternate-form-of="disp-formula3-0962280211432220" xlink:href="10.1177_0962280211432220-eq3.tif"/></disp-formula>
</p>
<p>The model given by (1) and (2) and its solution (3) have many different possible implementations and applications in meta-analysis. For example, it could be that in a classic frequentist meta-analysis across <italic>n</italic> trials we have a series of treatment contrasts <inline-formula id="ilm13-0962280211432220"><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" display="inline" id="mml-math13-0962280211432220"><mml:mrow><mml:msub><mml:mrow><mml:mi>Y</mml:mi></mml:mrow><mml:mrow><mml:mi>i</mml:mi></mml:mrow></mml:msub><mml:mrow><mml:mo/></mml:mrow><mml:mi>i</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn><mml:mo>,</mml:mo><mml:mo>…</mml:mo><mml:mo>,</mml:mo><mml:mi>n</mml:mi></mml:mrow></mml:math></inline-formula> with assumed known variances and common expectation so that the contrast for trial <italic>i</italic> can be expressed in terms of the unknown common treatment effect τ as:
<disp-formula id="disp-formula4-0962280211432220"><label>(4)</label><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" display="inline" id="math4-0962280211432220"><mml:mrow><mml:msub><mml:mrow><mml:mi>Y</mml:mi></mml:mrow><mml:mrow><mml:mi>i</mml:mi></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mi>τ</mml:mi><mml:mo>+</mml:mo><mml:msub><mml:mrow><mml:mi>ɛ</mml:mi></mml:mrow><mml:mrow><mml:mi>i</mml:mi></mml:mrow></mml:msub><mml:mrow><mml:mo/></mml:mrow><mml:mi>V</mml:mi><mml:mrow><mml:mo/><mml:mo>(</mml:mo></mml:mrow><mml:msub><mml:mrow><mml:mi>ɛ</mml:mi></mml:mrow><mml:mrow><mml:mi>i</mml:mi></mml:mrow></mml:msub><mml:mrow><mml:mo/><mml:mo>)</mml:mo></mml:mrow><mml:mo>=</mml:mo><mml:msubsup><mml:mrow><mml:mi>σ</mml:mi></mml:mrow><mml:mrow><mml:mi>i</mml:mi></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msubsup><mml:mo>.</mml:mo></mml:mrow></mml:math><graphic alternate-form-of="disp-formula4-0962280211432220" xlink:href="10.1177_0962280211432220-eq4.tif"/></disp-formula>
</p>
<p>To express (4) in terms of (1) and (2) requires that we have <inline-formula id="ilm14-0962280211432220"><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" display="inline" id="mml-math14-0962280211432220"><mml:mrow><mml:mtext mathvariant="bold">X</mml:mtext><mml:mo mathvariant="bold">=</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:math></inline-formula> as an <inline-formula id="ilm15-0962280211432220"><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" display="inline" id="mml-math15-0962280211432220"><mml:mrow><mml:mi>n</mml:mi><mml:mo>×</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:math></inline-formula> vector of <inline-formula id="ilm16-0962280211432220"><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" display="inline" id="mml-math16-0962280211432220"><mml:mrow><mml:mn>1</mml:mn><mml:mi>s</mml:mi></mml:mrow></mml:math></inline-formula>, <bold>Y</bold> as a <inline-formula id="ilm17-0962280211432220"><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" display="inline" id="mml-math17-0962280211432220"><mml:mrow><mml:mi>n</mml:mi><mml:mo>×</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:math></inline-formula> vector of the contrasts, <inline-formula id="ilm18-0962280211432220"><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" display="inline" id="mml-math18-0962280211432220"><mml:mrow><mml:mi>β</mml:mi><mml:mo>=</mml:mo><mml:mi>τ</mml:mi></mml:mrow></mml:math></inline-formula> as a simple scalar and <inline-formula id="ilm19-0962280211432220"><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" display="inline" id="mml-math19-0962280211432220"><mml:mrow><mml:mo>Σ</mml:mo></mml:mrow></mml:math></inline-formula> as a diagonal matrix with <inline-formula id="ilm20-0962280211432220"><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" display="inline" id="mml-math20-0962280211432220"><mml:mrow><mml:msub><mml:mrow><mml:mo>Σ</mml:mo></mml:mrow><mml:mrow><mml:mi>i</mml:mi><mml:mrow><mml:mo/></mml:mrow><mml:mi>j</mml:mi></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:msubsup><mml:mrow><mml:mi>σ</mml:mi></mml:mrow><mml:mrow><mml:mi>i</mml:mi></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msubsup><mml:mrow><mml:mo/></mml:mrow><mml:mi>i</mml:mi><mml:mo>=</mml:mo><mml:mi>j</mml:mi><mml:mrow><mml:mo/></mml:mrow><mml:mo>=</mml:mo><mml:mn>0</mml:mn><mml:mrow><mml:mo/></mml:mrow><mml:mi>i</mml:mi><mml:mo>≠</mml:mo><mml:mi>j</mml:mi></mml:mrow></mml:math></inline-formula>. In that case the inverse of <inline-formula id="ilm21-0962280211432220"><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" display="inline" id="mml-math21-0962280211432220"><mml:mrow><mml:mo>Σ</mml:mo></mml:mrow></mml:math></inline-formula> is given by <inline-formula id="ilm22-0962280211432220"><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" display="inline" id="mml-math22-0962280211432220"><mml:mrow><mml:msub><mml:mrow><mml:mo>Σ</mml:mo></mml:mrow><mml:mrow><mml:mi>i</mml:mi><mml:mrow><mml:mo/></mml:mrow><mml:mi>j</mml:mi></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mn>1</mml:mn><mml:mo>/</mml:mo><mml:msubsup><mml:mrow><mml:mi>σ</mml:mi></mml:mrow><mml:mrow><mml:mi>i</mml:mi></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msubsup><mml:mrow><mml:mo/></mml:mrow><mml:mi>i</mml:mi><mml:mo>=</mml:mo><mml:mi>j</mml:mi><mml:mrow><mml:mo/></mml:mrow><mml:mo>=</mml:mo><mml:mn>0</mml:mn><mml:mrow><mml:mo/></mml:mrow><mml:mi>i</mml:mi><mml:mo>≠</mml:mo><mml:mi>j</mml:mi></mml:mrow></mml:math></inline-formula> and hence we have that
<disp-formula id="disp-formula5-0962280211432220"><label>(5)</label><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" display="inline" id="math5-0962280211432220"><mml:mrow><mml:mrow><mml:mo/><mml:mo>(</mml:mo></mml:mrow><mml:msup><mml:mrow><mml:mi mathvariant="bold">X</mml:mi><mml:mo>'</mml:mo><mml:mo>Σ</mml:mo></mml:mrow><mml:mrow><mml:mo mathvariant="bold">-</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:msup><mml:mtext mathvariant="bold">X</mml:mtext><mml:msup><mml:mrow><mml:mo/><mml:mo>)</mml:mo></mml:mrow><mml:mrow><mml:mo mathvariant="bold">-</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:msup><mml:mo>=</mml:mo><mml:mfrac><mml:mrow><mml:mn>1</mml:mn></mml:mrow><mml:mrow><mml:munderover><mml:mo>∑</mml:mo><mml:mrow><mml:mi>i</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mrow><mml:mi>n</mml:mi></mml:mrow></mml:munderover><mml:mtext> 1</mml:mtext><mml:mo>/</mml:mo><mml:mi>σ</mml:mi><mml:msub><mml:mi/><mml:mrow><mml:mi>i</mml:mi></mml:mrow></mml:msub><mml:msup><mml:mi/><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msup></mml:mrow></mml:mfrac><mml:mrow><mml:mo/></mml:mrow><mml:msup><mml:mrow><mml:mi mathvariant="bold">X</mml:mi><mml:mo>'</mml:mo><mml:mo>Σ</mml:mo></mml:mrow><mml:mrow><mml:mo mathvariant="bold">-</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:msup><mml:mtext mathvariant="bold">Y</mml:mtext><mml:mo>=</mml:mo><mml:munderover><mml:mo>∑</mml:mo><mml:mrow><mml:mi>i</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mrow><mml:mi>n</mml:mi></mml:mrow></mml:munderover><mml:mfrac><mml:mrow><mml:mn>1</mml:mn></mml:mrow><mml:mrow><mml:msubsup><mml:mrow><mml:mi>σ</mml:mi></mml:mrow><mml:mrow><mml:mi>i</mml:mi></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msubsup></mml:mrow></mml:mfrac><mml:msub><mml:mrow><mml:mi>Y</mml:mi></mml:mrow><mml:mrow><mml:mi>i</mml:mi></mml:mrow></mml:msub><mml:mrow><mml:mo/></mml:mrow></mml:mrow></mml:math><graphic alternate-form-of="disp-formula5-0962280211432220" xlink:href="10.1177_0962280211432220-eq5.tif"/></disp-formula>
which thus yields from (3) the common standard fixed-effects meta-analytic solution for <inline-formula id="ilm23-0962280211432220"><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" display="inline" id="mml-math23-0962280211432220"><mml:mrow><mml:mover><mml:mrow><mml:mi>β</mml:mi></mml:mrow><mml:mi>∧</mml:mi></mml:mover></mml:mrow></mml:math></inline-formula>.</p>
<p>Alternatively, we could choose instead to model the individual group means for the various arms of the set of trials. For a series of two-armed parallel group trials we would now have twice as many summary statistics to model as previously. This is because the basic information now consists of mean responses per treatment arm as opposed to mean differences per trial. This formulation now presents us with a choice as to how we deal with (1) and (2). Either we model the main effect of trial as fixed or as random. The former approach requires us to augment the matrix <bold>X</bold> with a series of dummy variables to represent the trials in the meta-analysis. For example, if there are <italic>k</italic> two-armed trials, then one approach is to have a series of <italic>k</italic> vectors, each of length <inline-formula id="ilm24-0962280211432220"><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" display="inline" id="mml-math24-0962280211432220"><mml:mrow><mml:mn>2</mml:mn><mml:mi>k</mml:mi></mml:mrow></mml:math></inline-formula> (so that in terms of our general case we have <inline-formula id="ilm25-0962280211432220"><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" display="inline" id="mml-math25-0962280211432220"><mml:mrow><mml:mi>n</mml:mi><mml:mo>=</mml:mo><mml:mn>2</mml:mn><mml:mi>k</mml:mi></mml:mrow></mml:math></inline-formula>) and each with exactly two elements equal to 1, corresponding to the arms of a given trial, with all the other elements 0 and finally a treatment vector consisting of <inline-formula id="ilm26-0962280211432220"><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" display="inline" id="mml-math26-0962280211432220"><mml:mrow><mml:mi>k</mml:mi><mml:mn>1</mml:mn><mml:mi>s</mml:mi></mml:mrow></mml:math></inline-formula> and <inline-formula id="ilm27-0962280211432220"><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" display="inline" id="mml-math27-0962280211432220"><mml:mrow><mml:mi>k</mml:mi><mml:mn>0</mml:mn><mml:mi>s</mml:mi></mml:mrow></mml:math></inline-formula>. The variance covariance matrix will now have to be of order <inline-formula id="ilm28-0962280211432220"><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" display="inline" id="mml-math28-0962280211432220"><mml:mrow><mml:mn>2</mml:mn><mml:mi>k</mml:mi><mml:mo>×</mml:mo><mml:mn>2</mml:mn><mml:mi>k</mml:mi></mml:mrow></mml:math></inline-formula> with diagonal elements giving the variance, <inline-formula id="ilm29-0962280211432220"><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" display="inline" id="mml-math29-0962280211432220"><mml:mrow><mml:msubsup><mml:mrow><mml:mi>φ</mml:mi></mml:mrow><mml:mrow><mml:mi>j</mml:mi></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msubsup><mml:mrow><mml:mo/></mml:mrow><mml:mi>j</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn><mml:mo>,</mml:mo><mml:mo>…</mml:mo><mml:mo>,</mml:mo><mml:mn>2</mml:mn><mml:mi>k</mml:mi></mml:mrow></mml:math></inline-formula>) of the mean from a given arm from a given trial and the off-diagonal elements equal to zero. Note that if we have the means sorted by study then we have that the two arms from trial <italic>i</italic> have indices in terms of <italic>j</italic> of <inline-formula id="ilm30-0962280211432220"><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" display="inline" id="mml-math30-0962280211432220"><mml:mrow><mml:mi>j</mml:mi><mml:mo>=</mml:mo><mml:mn>2</mml:mn><mml:mi>i</mml:mi><mml:mo>-</mml:mo><mml:mn>1</mml:mn><mml:mrow><mml:mo/></mml:mrow><mml:mn>2</mml:mn><mml:mi>i</mml:mi></mml:mrow></mml:math></inline-formula>. The relationship with the formulation in terms of within-trial contrasts is that the variances of trial level contrasts are related to the variances of individuals arms by, <inline-formula id="ilm31-0962280211432220"><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" display="inline" id="mml-math31-0962280211432220"><mml:mrow><mml:msubsup><mml:mrow><mml:mi>σ</mml:mi></mml:mrow><mml:mrow><mml:mi>i</mml:mi></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msubsup><mml:mo>=</mml:mo><mml:msubsup><mml:mrow><mml:mi>φ</mml:mi></mml:mrow><mml:mrow><mml:mn>2</mml:mn><mml:mi>i</mml:mi><mml:mo>-</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msubsup><mml:mo>+</mml:mo><mml:msubsup><mml:mrow><mml:mi>φ</mml:mi></mml:mrow><mml:mrow><mml:mn>2</mml:mn><mml:mi>i</mml:mi></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msubsup></mml:mrow></mml:math></inline-formula>. Finally, the parameter vector <inline-formula id="ilm32-0962280211432220"><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" display="inline" id="mml-math32-0962280211432220"><mml:mrow><mml:mo>β</mml:mo></mml:mrow></mml:math></inline-formula> would now consist of <italic>k</italic> terms <inline-formula id="ilm33-0962280211432220"><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" display="inline" id="mml-math33-0962280211432220"><mml:mrow><mml:msub><mml:mrow><mml:mi>μ</mml:mi></mml:mrow><mml:mrow><mml:mi>i</mml:mi></mml:mrow></mml:msub><mml:mrow><mml:mo/></mml:mrow><mml:mi>i</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn><mml:mo>,</mml:mo><mml:mo>…</mml:mo><mml:mo>,</mml:mo><mml:mi>k</mml:mi></mml:mrow></mml:math></inline-formula> each corresponding to the mean under the control treatment in a given trial and a further term τ to represent the true difference between experimental and control treatment.</p>
<p>If this is done, then the solution given by (3) is identical to that which will be obtained by modeling the treatment contrasts as before. That is to say that the estimate for that element of <inline-formula id="ilm34-0962280211432220"><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" display="inline" id="mml-math34-0962280211432220"><mml:mrow><mml:mover><mml:mrow><mml:mo>β</mml:mo></mml:mrow><mml:mi>∧</mml:mi></mml:mover></mml:mrow></mml:math></inline-formula> that corresponds to the treatment effect and its estimated variance will be the same as before provided that the contrast for a given trial was previously calculated as the difference between the means of the two arms and its variance as the sum of the two variances.</p>
<p>An alternative approach, however, is to treat the main effect of trial as random. In that case the β term remains a simple scalar. However, now the variance-covariance matrix needs to become more complicated. It takes on a block diagonal form with a common element <inline-formula id="ilm35-0962280211432220"><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" display="inline" id="mml-math35-0962280211432220"><mml:mrow><mml:msup><mml:mrow><mml:mi>γ</mml:mi></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msup></mml:mrow></mml:math></inline-formula> added to the variance terms on the diagonal for the individual arms but also to those off-diagonal elements that were previously zero corresponding to the covariances between different arms but on the same trial. Estimation of this term is often difficult as it is the variance of a random effect that cannot be directly observed and for which the degrees of freedom, being a function of the number of trials, are usually much fewer than those used to estimate the within trial variances. Nevertheless, considerable progress has been made computationally in this area and many statistical packages now offer different ways of doing this.</p>
<p>If the main effect of trial is treated as random this now permits the recovery of inter-trial information. Whether such information exists or not depends on how balanced the trials are. To understand this point, consider a simple meta-analysis involving only two treatments. Two statistics that can be calculated from any trial are, first the difference between the means on each arm and second the overall mean response (averaged over all patients, whichever arm they are on). The first of these statistics is what we usually consider as carrying the message of the effect of treatment. Now consider the second statistic. This of course may be expected to vary from trial to trial because of differences in patients or protocols. However, if all trials are perfectly balanced, then there is no reason as to why this overall mean response should vary from trial to trial because of differences between treatments. If, however, the trials are unbalanced to differing degrees and if it is the case that one treatment is more efficacious than another, then we would expect that in those trials in which the proportion of patients on the more effective treatment was greater the overall mean response would be better than in those in which the proportion of patients on the more effective treatment was smaller. Thus, under these circumstances, the second statistic also reflects (albeit weakly) the difference between treatments when one trial is compared with another. It is thus a between-trial treatment estimate. If, however, every time we add a new trial we have to add a new parameter, as is the case in a fixed-effects model, then this between trial information is completely confounded with the main effect of trial. The consequence of this is that the estimation of treatment effects is reduced to a combination of within trial contrasts, these contrasts eliminating the main effect of trial. If, however, the main effect of trial is treated as a random effect, then this extra information can be ‘recovered’.</p>
<p>However, if all trials have employed one-to-one randomisation (or even the same identical unequal randomisation) then there will be very little if any information to recover and the solution for this approach will be (almost) identical to what it was before. See Senn<sup><xref ref-type="bibr" rid="bibr20-0962280211432220">20</xref></sup> for a discussion. This is not, however, in general true (for example the trials listed as Lewin (2007), Zhu (2003) and Johnston (1998a) in the Appendix all have strong imbalances in numbers). It would thus be inappropriate in this example to treat the main effect of trial as random. This point is sometimes overlooked. At stake here is the principal of concurrent control. This is the principle that requires that the effects of treatment should be calculated by comparison to a group of patients recruited at the same time under the same conditions and the same protocol: in fact the conditions that a classical randomised clinical trial delivers <italic>provided that</italic> the treatment effect is estimated as the difference between the two groups so recruited. If the principle of concurrent control is regarded as being sacrosanct, then one has no choice but to treat the main effect of trial as fixed. This is a different issue to the choice between fixed- and random-effects meta-analysis, which has to do with the way that the trial-by-treatment interaction is handled.</p>
<p>In this connection, it is interesting to note what ‘ICH E10’, that is to say the International Conference on Harmonisation document<sup><xref ref-type="bibr" rid="bibr21-0962280211432220">21</xref></sup> covering choice of control group, has to say on the subject. It describes four kinds of concurrently controlled trial and also considers a fifth about which it states:<disp-quote>
<p>The first four are concurrently controlled (the control group and test groups are chosen from the same population and treated concurrently), usually with random assignment to treatment; they are distinguished by the type of control treatment (listed above) used. External (historical) control groups, regardless of the comparator treatment, are considered together as the fifth type because of serious concerns about the ability of such trials to ensure comparability of test and control groups. (Section 1.3)</p></disp-quote></p>
<p>This is not just a theoretical concern. A striking example is offered by the TARGET study.<sup><xref ref-type="bibr" rid="bibr22-0962280211432220">22</xref>,<xref ref-type="bibr" rid="bibr23-0962280211432220">23</xref></sup> This large three-armed trial of treatments for osteoarthritis was run in two-sub-studies: lumiracoxib versus naproxen and lumiracoxib versus ibuprofen. Randomisation took place within but not between sub-studies. There was very good balance within sub-studies at baseline but striking imbalances between sub-studies.<sup><xref ref-type="bibr" rid="bibr24-0962280211432220">24</xref></sup></p>
<p>The above approaches can be generalised to cover sets of trials with more than two treatments. Similar decisions about modeling effects have to be made. In deciding to perform our meta-analysis of the diabetes data we decided to respect the principle of concurrent control. (This seemed particularly appropriate in view of the fact that most but not all studies modeled change scores.) That being so the main effect of trial had to be treated as fixed. Implementation of the GLS algorithm was considered to be easiest by modeling the means on treatment arms rather than contrasts. Accordingly, the way in which we proceeded was by modeling the effect on the 53 treatment arms. Implementation was in GenStat®, which is an all-purpose statistical package and programming language with powerful facilities for handling matrices. Of course many other packages could have been used.</p>
</sec>
<sec id="sec4-0962280211432220"><title>4 Presentation of results</title>
<p>The important thing to note about (3) is that the Aitken estimator consists of a linear combination of the <bold>Y</bold> with weights given by <inline-formula id="ilm36-0962280211432220"><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" display="inline" id="mml-math36-0962280211432220"><mml:mrow><mml:mrow><mml:mo/><mml:mo>(</mml:mo></mml:mrow><mml:msup><mml:mrow><mml:mtext mathvariant="bold">X</mml:mtext><mml:mo mathvariant="bold">'</mml:mo><mml:mo>Σ</mml:mo></mml:mrow><mml:mrow><mml:mo mathvariant="bold">-</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:msup><mml:mtext mathvariant="bold">X</mml:mtext><mml:msup><mml:mrow><mml:mo/><mml:mo>)</mml:mo></mml:mrow><mml:mrow><mml:mo mathvariant="bold">-</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:msup><mml:msup><mml:mrow><mml:mtext mathvariant="bold">X</mml:mtext><mml:mo mathvariant="bold">'</mml:mo><mml:mo>Σ</mml:mo></mml:mrow><mml:mrow><mml:mo mathvariant="bold">-</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:msup></mml:mrow></mml:math></inline-formula>. The estimator <inline-formula id="ilm37-0962280211432220"><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" display="inline" id="mml-math37-0962280211432220"><mml:mrow><mml:mover><mml:mrow><mml:mo>β</mml:mo></mml:mrow><mml:mi>∧</mml:mi></mml:mover></mml:mrow></mml:math></inline-formula> will have several elements. In our implementation the first <italic>k</italic> of these correspond to trial effects and are uninteresting. However, for <italic>t</italic> treatments, a further <inline-formula id="ilm38-0962280211432220"><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" display="inline" id="mml-math38-0962280211432220"><mml:mrow><mml:mi>t</mml:mi><mml:mo>-</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:math></inline-formula> correspond to treatment effects. In constructing the <bold>X</bold> matrix for a given implementation, a particular treatment has to be chosen as a reference treatment and the effects of the other treatments are then expressed as differences to this. In fact it is the columns of <inline-formula id="ilm39-0962280211432220"><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" display="inline" id="mml-math39-0962280211432220"><mml:mrow><mml:mrow><mml:mo/><mml:mo>(</mml:mo></mml:mrow><mml:msup><mml:mrow><mml:mtext mathvariant="bold">X</mml:mtext><mml:mo mathvariant="bold">'</mml:mo><mml:mo>Σ</mml:mo></mml:mrow><mml:mrow><mml:mo mathvariant="bold">-</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:msup><mml:mtext mathvariant="bold">X</mml:mtext><mml:msup><mml:mrow><mml:mo/><mml:mo>)</mml:mo></mml:mrow><mml:mrow><mml:mo mathvariant="bold">-</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:msup><mml:msup><mml:mrow><mml:mtext mathvariant="bold">X</mml:mtext><mml:mo mathvariant="bold">'</mml:mo><mml:mo>Σ</mml:mo></mml:mrow><mml:mrow><mml:mo mathvariant="bold">-</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:msup></mml:mrow></mml:math></inline-formula> that give the weights applied to the means from the treatment arms and it is the rows that correspond to a given parameter estimate. This means that the first <italic>k</italic> rows of the matrix are uninteresting but the last <inline-formula id="ilm40-0962280211432220"><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" display="inline" id="mml-math40-0962280211432220"><mml:mrow><mml:mi>t</mml:mi><mml:mo>-</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:math></inline-formula> show the weights that are used to produce the treatment estimate. One way of doing this is to produce a shade plot showing the weights graphically. Such a plot is illustrated in <xref ref-type="fig" rid="fig2-0962280211432220">Figure 2</xref>, for which placebo is taken as the reference treatment, and is quite revealing. It shows, for example, that as regard the estimate of the effect of miglitol compared to placebo three trials (Johnston, 1994, 1998a, b) are relevant but the rest are not.
<fig id="fig1-0962280211432220" position="float"><label>Figure 1.</label><caption><p>Network of trials and treatments for the diabetes example.</p></caption><graphic xlink:href="10.1177_0962280211432220-fig1.tif"/></fig>
<fig id="fig2-0962280211432220" position="float"><label>Figure 2.</label><caption><p>Shade plot for the diabetes network with placebo as the reference treatment: light colors positive weight, dark colors negative weight. Where there is no shading the mean response is not used.</p></caption><graphic xlink:href="10.1177_0962280211432220-fig2.tif"/>
</fig></p>
<p>However, if the reference treatment is changed to Rosiglitazone, which after placebo is the most studied treatment in the network, then a very different picture, which is illustrated by <xref ref-type="fig" rid="fig3-0962280211432220">Figure 3</xref> emerges. Now it can be seen that to connect miglitol to rosiglitazone, many other trials apart from just the three involving miglitol are used.
<fig id="fig3-0962280211432220" position="float"><label>Figure 3.</label><caption><p>Shade plot for the diabetes network with rosiglitazone as the reference treatment.</p></caption><graphic xlink:href="10.1177_0962280211432220-fig3.tif"/>
</fig></p>
<p>Indeed, no direct comparison of miglitol versus rosiglitazone was involved in our network (Tables <xref ref-type="table" rid="table1-0962280211432220">1</xref> and <xref ref-type="table" rid="table2-0962280211432220">2</xref>). The connection between these two treatments can only be done via indirect comparisons and so, using different pathways with a common comparator that was in this case only the placebo.</p>
<p>Like them, or hate them, there is no getting around the fact that many expect to see <italic>p</italic>-values as part and parcel of any meta-analysis. Given that there are a large number of contrasts to present (in our case with 10 treatments there are 45 possible contrasts) shade plots can also be an attractive way to present such results. An example is given in <xref ref-type="fig" rid="fig4-0962280211432220">Figure 4</xref> where it can easily be seen that placebo is significantly different from every other treatment at the 1% level of significance.
<fig id="fig4-0962280211432220" position="float"><label>Figure 4.</label><caption><p>Shade plot for <italic>p</italic>-values for fixed-effects analysis. Black <italic>p</italic> &lt; 0.01, dark grey 0.01&lt;<italic>p</italic> &lt; 0.05, light grey <italic>p</italic> &gt; 0.05.</p></caption><graphic xlink:href="10.1177_0962280211432220-fig4.tif"/>
</fig></p>
<p>On the other hand, conventional forest plots are not really relevant to a network meta-analysis. This is because conventionally such plots show the <italic>same</italic> treatment contrasts represented in a large number of trials. Here different trials were comparing different treatments. What one can do, however, is use an analogous plot to represent all the possible contrasts to a given reference treatment. Such a plot is given in <xref ref-type="fig" rid="fig5-0962280211432220">Figure 5</xref>.
<fig id="fig5-0962280211432220" position="float"><label>Figure 5.</label><caption><p>Contrasts and 95% confidence intervals with placebo as the reference treatment. GLS analysis (fixed-effects analysis).</p></caption><graphic xlink:href="10.1177_0962280211432220-fig5.tif"/>
</fig></p>
<p>A useful way of showing all contrasts in a trial comparing a number of treatments is given in the book by Hsu.<sup><xref ref-type="bibr" rid="bibr25-0962280211432220">25</xref>,<xref ref-type="bibr" rid="bibr26-0962280211432220">26</xref></sup> This approach is illustrated for our example in <xref ref-type="fig" rid="fig6-0962280211432220">Figure 6</xref>. Placebo is taken as a reference treatment and arbitrarily given the value 0 All other treatments are expressed as differences to placebo and plotted twice: once on the <italic>X</italic> axis and once on the <italic>Y</italic> axis. Each of the 45 possible pairwise contrasts is represented by a point in the <inline-formula id="ilm41-0962280211432220"><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" display="inline" id="mml-math41-0962280211432220"><mml:mrow><mml:mi>X</mml:mi><mml:mrow><mml:mo/></mml:mrow><mml:mi>Y</mml:mi></mml:mrow></mml:math></inline-formula> plane and the same is true for the associated 95% confidence limits which are joined to the point estimates by diagonal lines. It is the distance of these from the dashed diagonal line rising from bottom left to top right that indicates the magnitude of the effect. Note that because only the unique <inline-formula id="ilm42-0962280211432220"><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" display="inline" id="mml-math42-0962280211432220"><mml:mrow><mml:mrow><mml:mo/><mml:mo>[</mml:mo></mml:mrow><mml:mn>10</mml:mn><mml:mo>×</mml:mo><mml:mrow><mml:mo/><mml:mo>(</mml:mo></mml:mrow><mml:mn>10</mml:mn><mml:mo>-</mml:mo><mml:mn>1</mml:mn><mml:mrow><mml:mo/><mml:mo>)</mml:mo></mml:mrow><mml:mrow><mml:mo/><mml:mo>]</mml:mo></mml:mrow><mml:mo>/</mml:mo><mml:mn>2</mml:mn><mml:mo>=</mml:mo><mml:mn>45</mml:mn></mml:mrow></mml:math></inline-formula> contrasts are plotted corresponding to all possible unique pairwise comparisons, we do not have <inline-formula id="ilm43-0962280211432220"><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" display="inline" id="mml-math43-0962280211432220"><mml:mrow><mml:mn>10</mml:mn><mml:mo>×</mml:mo><mml:mn>10</mml:mn><mml:mo>=</mml:mo><mml:mn>100</mml:mn></mml:mrow></mml:math></inline-formula> points. Hence a given treatment sometimes appears on the <italic>X</italic> axis and sometimes on the <italic>Y</italic> axis. For example corresponding to the placebo position on the <italic>X</italic> axis there are five contrasts (metformin, pioglitazone, miglitol, benfluorex, acarbose) and corresponding to the position on the <italic>Y</italic> axis there are four contrasts (rosiglitazone, vildagliptin, sitagliptin and SUalone) whereas vildagliptin appears only on the <italic>X</italic> axis. It is important to appreciate in looking at the diagram that if one wishes to interpret the contrast in terms of the <italic>Y</italic> value minus the <italic>X</italic> value that a given treatment can sometimes be the former and sometimes the latter. Significant contrasts are represented by solid diamonds and solid lines and non-significant ones by open diamonds and dashed lines. No adjustment for multiplicity has been made and this is the major difference to the sort of thing that Hsu does in his book.
<fig id="fig6-0962280211432220" position="float"><label>Figure 6.</label><caption><p>Hsu mean-mean plot for the network of 10 trials showing all 45 pairwise contrasts and their 95% confidence limits. Significant contrasts are show as a solid line with a solid diamond. Non-significant contrasts are shown as a dashed line with an open diamond.</p></caption><graphic xlink:href="10.1177_0962280211432220-fig6.tif"/>
</fig></p>
<p>The plot is rather busy but a lot of information is conveyed. It is quite easy to see that treatments are significantly different to placebo, including ‘SU alone’ (which is a point we pick up in the discussion) but also that most other treatments are different to SU alone and that generally rosiglitazone appears to be the treatment with the biggest effect.</p>
</sec>
<sec id="sec5-0962280211432220"><title>5 Heterogeneity and iteratively re-weighted least squares</title>
<p>The analysis using generalised least squares is the generalisation to more than two treatments of the standard fixed-effects analysis weighting only by internal estimates of precision. There are two standard justifications of such a fixed-effects analysis. The first one relies on the equality of all treatments under the null hypothesis. This is a standard Fisherian approach to significance testing that includes as part of the hypothesis being tested that there can be no interaction.<sup><xref ref-type="bibr" rid="bibr27-0962280211432220">27</xref>,<xref ref-type="bibr" rid="bibr28-0962280211432220">28</xref></sup> Thus, if the treatments are identical there can be no treatment-by-trial interaction,<sup><xref ref-type="bibr" rid="bibr29-0962280211432220">29</xref></sup> that is to say the strongest hypothesis possible is that the treatments are identical in every trial.</p>
<p>Now consider the extension of this to a meta-analysis of a complete set of trials each involving 10 treatments. Of course, this is not at all what we have here but it serves to pose the problem. In this case the null hypothesis in question would be the hypothesis that all ten treatments were identical in all effects. It only requires one treatment to be different from the others for this hypothesis to be invalid. Thus to compare any given two treatments using all the data requires an additional assumption about the other eight that are not involved in the given comparison. It may be queried, therefore, as to whether the null hypothesis that all treatments are identical can be used as a justification for a fixed-effects analysis if the main purpose of that analysis is not to test this ‘global’ hypothesis but to permit pairwise contrasts to be estimated.</p>
<p>Furthermore, one might argue that in fact the situation is far worse in a network meta-analysis because the remote influence of interaction in trials as well as treatments not directly involved in a given pairwise comparison. See Lumley for a discussion of some issues.<sup><xref ref-type="bibr" rid="bibr4-0962280211432220">4</xref></sup></p>
<p>The second standard justification for a fixed-effects analysis is that there is, in fact, no evidence of heterogeneity present. This is not so much a reason for preferring a fixed-effects to a random-effects analysis but rather a circumstance that will lead fixed- and random-effects analyses to produce very similar results.</p>
<p>Unfortunately, analysis of the network of trials suggests considerable heterogeneity in response. The sum of the squared standardised residuals is <inline-formula id="ilm44-0962280211432220"><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" display="inline" id="mml-math44-0962280211432220"><mml:mrow><mml:mn>97</mml:mn><mml:mo>.</mml:mo><mml:mn>0</mml:mn></mml:mrow></mml:math></inline-formula> whereas the degrees of freedom are <inline-formula id="ilm45-0962280211432220"><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" display="inline" id="mml-math45-0962280211432220"><mml:mrow><mml:mrow><mml:mo/><mml:mo>(</mml:mo></mml:mrow><mml:mn>53</mml:mn><mml:mo>-</mml:mo><mml:mn>1</mml:mn><mml:mrow><mml:mo/><mml:mo>)</mml:mo></mml:mrow><mml:mo>-</mml:mo><mml:mrow><mml:mo/><mml:mo>(</mml:mo></mml:mrow><mml:mn>26</mml:mn><mml:mo>-</mml:mo><mml:mn>1</mml:mn><mml:mrow><mml:mo/><mml:mo>)</mml:mo></mml:mrow><mml:mo>-</mml:mo><mml:mrow><mml:mo/><mml:mo>(</mml:mo></mml:mrow><mml:mn>10</mml:mn><mml:mo>-</mml:mo><mml:mn>1</mml:mn><mml:mrow><mml:mo/><mml:mo>)</mml:mo></mml:mrow><mml:mo>=</mml:mo><mml:mn>18</mml:mn></mml:mrow></mml:math></inline-formula>. One approach to dealing with this is to use iteratively re-weighted least squares (IRLS). To apply IRLS, the residual variance under the GLS model is inflated by the ratio <inline-formula id="ilm46-0962280211432220"><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" display="inline" id="mml-math46-0962280211432220"><mml:mrow><mml:mn>97</mml:mn><mml:mo>.</mml:mo><mml:mn>0</mml:mn><mml:mo>/</mml:mo><mml:mn>18</mml:mn></mml:mrow></mml:math></inline-formula>. This term is then added to the individual variances for the arms, the GLS algorithm is applied to the inflated variances and the process proceeds iteratively until the sum of the squared standardised residuals is equal to the residual degrees of freedom.<sup><xref ref-type="bibr" rid="bibr4-0962280211432220">4</xref>,<xref ref-type="bibr" rid="bibr30-0962280211432220">30</xref>,<xref ref-type="bibr" rid="bibr31-0962280211432220">31</xref></sup></p>
<p>We prefer to consider the matter from this perspective since it does not commit us to giving any particular meaning to the extra variance in terms of a model. In this philosophy, we simply note that viewing the data as a whole the scatter is inadequately represented by the fixed-effects model and inflation of variance is required. Analogous approaches are used in many other areas of applied statistics modeling. Rescaling of standards errors of parameter estimates in Poisson regression using residual deviance is an example.<sup><xref ref-type="bibr" rid="bibr32-0962280211432220">32</xref></sup></p>
<p>However, if one prefers to think of this in terms of a model, the implicit model requires a modification of the expression for the variance of a given arm so that instead of having <inline-formula id="ilm47-0962280211432220"><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" display="inline" id="mml-math47-0962280211432220"><mml:mrow><mml:msubsup><mml:mrow><mml:mi>φ</mml:mi></mml:mrow><mml:mrow><mml:mi>j</mml:mi></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msubsup></mml:mrow></mml:math></inline-formula> as the variance term for such an arm, we now have <inline-formula id="ilm48-0962280211432220"><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" display="inline" id="mml-math48-0962280211432220"><mml:mrow><mml:msup><mml:mrow><mml:mi>ω</mml:mi></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msup><mml:mo>+</mml:mo><mml:msubsup><mml:mrow><mml:mi>φ</mml:mi></mml:mrow><mml:mrow><mml:mi>j</mml:mi></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msubsup></mml:mrow></mml:math></inline-formula> as the variance where <inline-formula id="ilm49-0962280211432220"><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" display="inline" id="mml-math49-0962280211432220"><mml:mrow><mml:msup><mml:mrow><mml:mi>ω</mml:mi></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msup></mml:mrow></mml:math></inline-formula>is a term common to all. Note that unlike the case where the <italic>main effect</italic> of trial is treated as random, the matrix <inline-formula id="ilm50-0962280211432220"><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" display="inline" id="mml-math50-0962280211432220"><mml:mrow><mml:mo>Σ</mml:mo></mml:mrow></mml:math></inline-formula> has a simple, and not block diagonal form and this means that there are no <italic>covariance</italic> terms <inline-formula id="ilm51-0962280211432220"><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" display="inline" id="mml-math51-0962280211432220"><mml:mrow><mml:msup><mml:mrow><mml:mi>ω</mml:mi></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msup></mml:mrow></mml:math></inline-formula> and that hence <inline-formula id="ilm52-0962280211432220"><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" display="inline" id="mml-math52-0962280211432220"><mml:mrow><mml:msup><mml:mrow><mml:mi>ω</mml:mi></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msup></mml:mrow></mml:math></inline-formula> is <italic>not</italic> eliminated from variances of contrasts by differencing. Thus a genuine increase in variance occurs.</p>
<p>The result of applying this procedure to this example is illustrated in <xref ref-type="fig" rid="fig7-0962280211432220">Figure 7</xref> where it can be seen that there is a considerable increase in the width of the confidence intervals for the various contrasts compared to <xref ref-type="fig" rid="fig5-0962280211432220">Figure 5</xref>. One interpretation of such an analysis is that it constitutes a ‘random effects’ analysis. However, one should not push the analogy with classical meta-analysis of two treatments too far. One problem with making the analogy is that a single variance inflation factor is involved. However, one could in fact think of many possible random-effect variances. If each of the 45 possible treatment comparisons had been studied in a large set of trials, each could have led to an independent meta-analysis each estimating a different random-effects variance. In other words one could imagine 45 random-effect variances and not just one. Of course there will be some dependence between them since A is compared to B and B to C but also A to C and so forth. Nevertheless at least nine different variances could plausibly be entertained and it clearly involves a strong assumption to say that a meta-analysis involving a single random-effects variance is an adequate generalisation to the comparison of ten treatments of the case when only two treatments are compared. We shall pick this point up again in the discussion.
<fig id="fig7-0962280211432220" position="float"><label>Figure 7.</label><caption><p>Contrasts and 95% confidence intervals with placebo as the reference treatment. IRLS analysis (random-effects analysis).</p></caption><graphic xlink:href="10.1177_0962280211432220-fig7.tif"/>
</fig></p>
<p>Of course the excess of variance may not just be a reflection of treatment-by-trial interaction. It may simply reflect, for whatever reason, including possibly technical error, that in some cases the declared variances from the given trials are lower than they should be. It is, in fact, inherent to meta-analysis based on weighting results by observed precision that variances of treatment estimates are underestimated.<sup><xref ref-type="bibr" rid="bibr20-0962280211432220">20</xref>,<xref ref-type="bibr" rid="bibr29-0962280211432220">29</xref>,<xref ref-type="bibr" rid="bibr33-0962280211432220">33</xref></sup> A technical issue is raised by the presence of a three-armed trial in our set. How should the variances be handled? There is no problem in the fixed-effects analysis, since this has a main effect of trial and conditional independence of the treatment means given the trial effect is assumed. For a random-effect component, however, things are not so simple. In this case any possible biases, however, would seem to be small compared to other uncertainties regarding appropriate variance structure.</p>
</sec>
<sec id="sec6-0962280211432220"><title>6 Analogies to Bayesian approaches</title>
<p>Great claims are sometimes made for the inherent ability of the Bayesian framework to handle network meta-analysis and its greater flexibility. In our view this choice of implementation of framework for inference, Bayesian or frequentist, may be less important than other choices regarding the modeling of effects. A key issue to be faced, as we have already discussed and irrespective as to whether a fixed- or random-effects analysis is envisaged is the handling of the main effect of trial. For reasons discussed in (2) we do not recommend the use of a single random trial effect whether in the Bayesian or frequentist framework. To treat this as random in a Bayesian framework is to model it as a single effect to be modeled across trials, with, of course, its own prior distribution. If it is treated as fixed a separate distribution and an uninformative prior is introduced for each trial. This is analogous to the difference discussed in Section 3 where depending upon which approach was used, the trial effect was handled either in (3) as part of the <inline-formula id="ilm53-0962280211432220"><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" display="inline" id="mml-math53-0962280211432220"><mml:mrow><mml:mo>Σ</mml:mo></mml:mrow></mml:math></inline-formula> structure (random) or the <bold>X</bold> structure (fixed). Where the Bayesian approach has <italic>potential</italic> advantages is where the degrees of freedom for handling a particular component of variation are scarce. However, as has been pointed out, this advantage cannot be realised if flat ‘uninformative’ prior distributions are used.<sup><xref ref-type="bibr" rid="bibr34-0962280211432220">34</xref></sup> A useful discussion and illustration of Bayesian approaches is provided by the ISPOR task force report.<sup><xref ref-type="bibr" rid="bibr35-0962280211432220">35</xref></sup></p>
<p>As regards the handling of true random effects, that is to say random trial by treatment interactions, a particular difficulty that any network analysis faces is that there may be many of these, rather than just one as in a conventional meta-analysis, that one could face. As far as we are aware very little work on this issue has been done whether in a frequentist or Bayesian framework.</p>
</sec>
<sec id="sec7-0962280211432220"><title>7 Issues, discussion and conclusion</title>
<p>Our experience in carrying out this meta-analysis has been rather mixed. On the one hand we can claim that some sort of formal exploration of the data is valuable. Whether or not one chooses to combine the data from different trials examining different treatments, in practice medical practitioners have to make a choice of therapy. Thus, if the choice is not to be based on mere prejudice or habit, the comparison is one that has to be made by looking at the evidence and that cannot be avoided. Our belief is that a formal analysis of the data can be valuable, provided that its limitations are recognised.</p>
<p>The example illustrated here has very considerable heterogeneity. This makes it possible to come to very different conclusions depending on whether this heterogeneity is taken into account in order to inflate the variances or not. Comparison of <xref ref-type="fig" rid="fig7-0962280211432220">Figure 7</xref> and <xref ref-type="fig" rid="fig5-0962280211432220">Figure 5</xref> shows that the picture can change considerably when such variance inflation is implemented.</p>
<p>Nevertheless, some conclusions are qualitatively unaffected. It is still the case, whichever analysis is used that, acarbose, benfluorex, miglitol, metformin, pioglitazone and rosiglitazone show good evidence of efficacy compared to placebo and even for vildagliptin the result is also still significant. Only for sitagliptin and sulfonylurea alone is there an important change in qualitative terms. However, this is precisely where referring back to the shade plot given in <xref ref-type="fig" rid="fig2-0962280211432220">Figure 2</xref> is useful. Here it can be seen that the information for vildagliptin and sitagliptin comes from a single trial in each case. The fact that the fixed-effect analysis is highly significant reflects the significance in these trials. It could be argued that it is inappropriate to inflate the variances for these contrasts using information from other trials not involving these treatments.</p>
<p>This shows, in fact, that one should be cautious about interpreting the ‘random effects’ analysis. Only one random effect, <inline-formula id="ilm54-0962280211432220"><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" display="inline" id="mml-math54-0962280211432220"><mml:mrow><mml:msup><mml:mrow><mml:mi>ω</mml:mi></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msup></mml:mrow></mml:math></inline-formula>, is allowed for but one could envisage many. It is sometimes suggested that a random-effects analysis is an appropriate way of allowing for the uncertainty that would apply to any future study whereas a fixed-effects analysis is a way of describing what happened to the patients who were studied. In our opinion it is rather naïve, even in the case where only two treatments are being compared to assume that random-effects analysis accounts for all uncertainty about the way effects can vary from trial to trial. In a case like this however, such reservations apply <italic>a fortiori</italic>. As already mentioned, it is most reasonable in our view to regard the IRLS approach as being a pragmatic inflation of variances to account for the observed lack of fit in the GLS approach. It should not be interpreted as accounting for all sources of uncertainty and its justification is rather the pragmatic one that if decisions have to be made, then in the absence of any other information, one may as well make them on the basis of an analysis of the data at hand that treats the trials as if they were exchangeable. Of course, some observers would simply claim that the disparity between <xref ref-type="fig" rid="fig7-0962280211432220">Figure 7</xref> and <xref ref-type="fig" rid="fig5-0962280211432220">Figure 5</xref> simply shows that more work needs to be done. Our reply would be that it may take rather a large number of trials to resolve all uncertainties and in the meantime decisions about treating patients still have to be made.</p>
<p>Nevertheless, as Thompson has argued,<sup><xref ref-type="bibr" rid="bibr36-0962280211432220">36</xref></sup> it is important to investigate possible explanations for heterogeneity. In this connection, <xref ref-type="fig" rid="fig8-0962280211432220">Figure 8</xref> may be revealing. This figure represents the contribution to the overall chi-square for heterogeneity of different trials. This contribution is calculated by forming the ratio of the residual from the GLS regression to the within trial standard error, squaring the ratio and summing by trial. Several features of interest appear. For example, some trials make no contribution to the total. This is inevitable where there is only one two-armed trial in which a given treatment appears, since the residual will then be zero. Such is the case with the trials Hermansen (2007) and Garber (2008).
<fig id="fig8-0962280211432220" position="float"><label>Figure 8.</label><caption><p>Plot showing contribution of each study to the overall <italic>Q</italic> statistic for heterogeneity.</p></caption><graphic xlink:href="10.1177_0962280211432220-fig8.tif"/>
</fig></p>
<p>The figure shows that an enormous contribution is made by one trial: DeFronzo (1995).<sup><xref ref-type="bibr" rid="bibr37-0962280211432220">37</xref></sup> As it turns out, this trial is one of the four comparing metformin to placebo. It is thus possible to analyse this subgroup of four using a conventional meta-analysis (ignoring the acarbose arm of Willms (1999)).<sup><xref ref-type="bibr" rid="bibr32-0962280211432220">32</xref></sup> The results show a high degree of heterogeneity for the four trials alone with a <italic>Q</italic> statistic of 52 on 3 degrees of freedom. Amongst these trials De Fronzo (1995) is the most out of step with a much bigger treatment effect, as is illustrated by the conventional forest plot in <xref ref-type="fig" rid="fig9-0962280211432220">Figure 9</xref>.
<fig id="fig9-0962280211432220" position="float"><label>Figure 9.</label><caption><p>Conventional forest plot showing treatment contrasts and 95% confidence intervals for metformin vs placebo for the four trials comparing these treatments. Also shown are the corresponding estimates and confidence intervals for fixed- and random-effects analyses.</p></caption><graphic xlink:href="10.1177_0962280211432220-fig9.tif"/>
</fig></p>
<p>This immediately points to one of the paradoxes of random-effects meta-analysis, a paradox that is highlighted when a network in involved. Consider the authors of the trial in Sitagliptin reported in Hermansen.<sup><xref ref-type="bibr" rid="bibr38-0962280211432220">38</xref></sup> According to <xref ref-type="fig" rid="fig5-0962280211432220">Figure 5</xref> the result is highly significant. Once the general heterogeneity is added to the mix the result is no longer significant. But, the authors might protest, their trial has no effect on the general heterogeneity measure, whereas the fact that a number of trials of metformin disagree with each other is now taken, mysteriously, to make the results that they have presented less reliable. Is this reasonable?</p>
<p>Returning to the four trials of metformin, another issue is raised. Consider the two large studies DeFronzo (1995) and Lewin (2007).<sup><xref ref-type="bibr" rid="bibr39-0962280211432220">39</xref></sup> It is quite clear that these alone give very different messages but is it reasonable to pool them in the first place? A return to the protocols shows that in the DeFronzo (1995), patients were titrated to a maximum dose of 2500 mg daily. On the other hand in the case of Lewin (2007) there were actually three groups of metformin that were pooled for analysis: one had a once daily dose of 1500 mg and two had a total daily dose of 2000 mg delivered either once a day (1 × 2000 mg) or twice a day (2 × 1000 mg). These were pooled by the authors for analysis. Thus the average daily dose of metformin in Lewin (2007) was
<disp-formula id="disp-formula6-0962280211432220"><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" display="inline" id="math6-0962280211432220"><mml:mrow><mml:mfrac><mml:mrow><mml:mn>1500</mml:mn><mml:mi> </mml:mi><mml:mtext>mg</mml:mtext><mml:mo>+</mml:mo><mml:mn>2</mml:mn><mml:mo>×</mml:mo><mml:mn>2000</mml:mn><mml:mi> </mml:mi><mml:mtext>mg</mml:mtext></mml:mrow><mml:mrow><mml:mn>3</mml:mn></mml:mrow></mml:mfrac><mml:mo>≈</mml:mo><mml:mn>1800</mml:mn><mml:mi> </mml:mi><mml:mtext>mg</mml:mtext><mml:mrow><mml:mo/></mml:mrow></mml:mrow></mml:math><graphic alternate-form-of="disp-formula6-0962280211432220" xlink:href="10.1177_0962280211432220-eq6.tif"/></disp-formula>
where as the maximum dose in DeFronzo was 2500 mg. Are the doses in Lewin (2007) comparable to DeFronzo (1995)? Does the fact that quite different approaches to dosing were used (fixed versus titration) mean that they should not be pooled? There are many instances in drug regulation where a regulator would reject as quite inappropriate such a pooling. Can it be justified in meta-analysis?</p>
<p>This returns us to the issue of testing of hypotheses previously raised. Pooling is legitimate if one is testing the hypothesis that metformin has no effect on HbA1c. If, however, the hypothesis was rejected by pooling trials with different doses, dose schedules or formulations, then even if the same molecule is involved one should not necessarily be surprised to find heterogeneity. The problem that this raises is that we have a network meta-analysis of 10 treatments defined by 8 molecules plus two forms of control but clearly by considering details of administration one could raise the number of treatments considerably and this would have a major effect on results.</p>
<p>A further possible source of heterogeneity is time. There is a difference of 12 years between the DeFronzo and Lewin studies. In other indications the mean ‘response’ under placebo has been shown to change over time. For instance, Julious and Wang<sup><xref ref-type="bibr" rid="bibr40-0962280211432220">40</xref></sup> were able to illustrate the phenomenon of ‘placebo creep’ in 81 trials of paroxetein in depression.</p>
<p>To raise a further issue, it is also well known that where baseline risk differs, choice of scale can have an important influence on heterogeneity. Chappel et al.<sup><xref ref-type="bibr" rid="bibr41-0962280211432220">41</xref></sup> have shown, for example, that much of the apparent difference in effect on HbA1c by treatments for diabetes can be explained in differences in baseline risk. We have also investigated this and found a similar effect but reserve exposition of this for a further paper. However, a possible implication is that this applies not just between but within studies. This in turn might imply that a patient level analysis with baselines as a covariate and perhaps even on the log scale would permit further heterogeneity to be explained. Unfortunately, this is not possible based on summary statistics available.</p>
<p>An interesting result of the meta-analysis is that there is a suggestion that sulfonylurea alone is more efficacious than when given in connection with placebo. The evidence for this is, of course, indirect. and <xref ref-type="table" rid="table1-0962280211432220">Table 1</xref> shows that there were no trials comparing sulfonylurea alone to placebo but that it was compared to acarbose, metformin and rosiglitazone in each case in one open trial. One should be cautious, therefore, in reading too much into this finding. One possible explanation, however, is that it is easier for physicians to optimise standard therapy when given in an open fashion and that blinding trials interferes with flexibility. We also remind the reader, however, of a point made in the introduction: the purpose of this article is to share issues and experiences in carrying out a meta-analysis. It should not be taken as providing a definitive statement about the treatment of diabetes. Further exploration of the data would surely be necessary before one did this.</p>
<p>More generally, however, it seems to us that although one must accept that any conclusions based on such a network meta-analysis must be made cautiously one should be careful in concluding that is an inherent weakness of such an analysis. The fact that one ‘widens the net’ by looking at more treatments may bring one face to face with inherent uncertainties. It would be a mistake, however, to assume that such uncertainties are not present just because one has not looked for them.</p>
</sec>
</body>
<back><ack>
<title>Acknowledgements</title>
<p>We are grateful to Keith O’Rourke for helpful comments on an earlier version and to Christine Bouillant for her help in extracting the data for synthesis. We thank an anonymous referee for a careful reading and helpful comments. Any errors that remain are ours. AS and SS gratefully acknowledge funding from Servier.</p></ack>
<ref-list>
<title>References</title>
<ref id="bibr1-0962280211432220"><label>1</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Eddy</surname><given-names>DM</given-names></name><name><surname>Hasselblad</surname><given-names>V</given-names></name><name><surname>Schacker</surname><given-names>R</given-names></name></person-group>. <article-title>An introduction to a Bayesian method for Meta-analysis: the confidence profile method</article-title>. <source>Med Decis Making</source> <year>1991</year>; <volume>10</volume>: <fpage>15</fpage>–<lpage>23</lpage>.</citation></ref>
<ref id="bibr2-0962280211432220"><label>2</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Chung</surname><given-names>H</given-names></name><name><surname>Lumley</surname><given-names>T</given-names></name></person-group>. <article-title>Graphical exploration of network meta-analysis data: the use of multidimensional scaling</article-title>. <source>Clin Trials</source> <year>2008</year>; <volume>5</volume>(<issue>4</issue>): <fpage>301</fpage>–<lpage>307</lpage>.</citation></ref>
<ref id="bibr3-0962280211432220"><label>3</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Thijs</surname><given-names>V</given-names></name><name><surname>Lemmens</surname><given-names>R</given-names></name><name><surname>Fieuws</surname><given-names>S</given-names></name></person-group>. <article-title>Network meta-analysis: simultaneous meta-analysis of common antiplatelet regimens after transient ischaemic attack or stroke</article-title>. <source>Eur Heart J</source> <year>2008</year>; <volume>29</volume>(<issue>9</issue>): <fpage>1086</fpage>–<lpage>1092</lpage>.</citation></ref>
<ref id="bibr4-0962280211432220"><label>4</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lumley</surname><given-names>T</given-names></name></person-group>. <article-title>Network meta-analysis for indirect treatment comparisons</article-title>. <source>Stat Med</source> <year>2002</year>; <volume>21</volume>(<issue>16</issue>): <fpage>2313</fpage>–<lpage>2324</lpage>.</citation></ref>
<ref id="bibr5-0962280211432220"><label>5</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Song</surname><given-names>F</given-names></name><name><surname>Altman</surname><given-names>DG</given-names></name><name><surname>Glenny</surname><given-names>AM</given-names></name><name><surname>Deeks</surname><given-names>JJ</given-names></name></person-group>. <article-title>Validity of indirect comparison for estimating efficacy of competing interventions: empirical evidence from published meta-analyses</article-title>. <source>BMJ</source> <year>2003</year>; <volume>326</volume>(<issue>7387</issue>): <fpage>472</fpage>–<lpage>472</lpage>.</citation></ref>
<ref id="bibr6-0962280211432220"><label>6</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Elliott</surname><given-names>WJ</given-names></name><name><surname>Meyer</surname><given-names>PM</given-names></name></person-group>. <article-title>Incident diabetes in clinical trials of antihypertensive drugs: a network meta-analysis</article-title>. <source>Lancet</source> <year>2007</year>; <volume>369</volume>(<issue>9557</issue>): <fpage>201</fpage>–<lpage>207</lpage>.</citation></ref>
<ref id="bibr7-0962280211432220"><label>7</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lu</surname><given-names>G</given-names></name><name><surname>Ades</surname><given-names>AE</given-names></name></person-group>. <article-title>Combination of direct and indirect evidence in mixed treatment comparisons</article-title>. <source>Stat Med</source> <year>2004</year>; <volume>23</volume>(<issue>20</issue>): <fpage>3105</fpage>–<lpage>3124</lpage>.</citation></ref>
<ref id="bibr8-0962280211432220"><label>8</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lu</surname><given-names>G</given-names></name><name><surname>Ades</surname><given-names>AE</given-names></name><name><surname>Sutton</surname><given-names>AJ</given-names></name><name><surname>Cooper</surname><given-names>NJ</given-names></name><name><surname>Briggs</surname><given-names>AH</given-names></name><name><surname>Caldwell</surname><given-names>DM</given-names></name></person-group>. <article-title>Meta-analysis of mixed treatment comparisons at multiple follow-up times</article-title>. <source>Stat Med</source> <year>2007</year>; <volume>26</volume>(<issue>20</issue>): <fpage>3681</fpage>–<lpage>3699</lpage>.</citation></ref>
<ref id="bibr9-0962280211432220"><label>9</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Caldwell</surname><given-names>DM</given-names></name><name><surname>Ades</surname><given-names>AE</given-names></name><name><surname>Higgins</surname><given-names>JP</given-names></name></person-group>. <article-title>Simultaneous comparison of multiple treatments: combining direct and indirect evidence</article-title>. <source>BMJ</source> <year>2005</year>; <volume>331</volume>(<issue>7521</issue>): <fpage>897</fpage>–<lpage>900</lpage>.</citation></ref>
<ref id="bibr10-0962280211432220"><label>10</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Salanti</surname><given-names>G</given-names></name><name><surname>Higgins</surname><given-names>JP</given-names></name><name><surname>Ades</surname><given-names>AE</given-names></name><name><surname>Ioannidis</surname><given-names>JP</given-names></name></person-group>. <article-title>Evaluation of networks of randomized trials</article-title>. <source>Stat Meth Med Res</source> <year>2008</year>; <volume>17</volume>(<issue>3</issue>): <fpage>279</fpage>–<lpage>301</lpage>.</citation></ref>
<ref id="bibr11-0962280211432220"><label>11</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Fisher</surname><given-names>LD</given-names></name><name><surname>Gent</surname><given-names>M</given-names></name><name><surname>Buller</surname><given-names>HR</given-names></name></person-group>. <article-title>Active-control trials: how would a new agent compare with placebo? A method illustrated clopidogrel, aspirin, and placebo</article-title>. <source>Am Heart J</source> <year>2001</year>; <volume>141</volume>(<issue>1</issue>): <fpage>26</fpage>–<lpage>32</lpage>.</citation></ref>
<ref id="bibr12-0962280211432220"><label>12</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hasselblad</surname><given-names>V</given-names></name><name><surname>Kong</surname><given-names>DF</given-names></name></person-group>. <article-title>Statistical methods for comparison to placebo in active-control studies</article-title>. <source>Drug Inform J</source> <year>2001</year>; <volume>35</volume>: <fpage>435</fpage>–<lpage>449</lpage>.</citation></ref>
<ref id="bibr13-0962280211432220"><label>13</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hirotsu</surname><given-names>C</given-names></name><name><surname>Yamada</surname><given-names>L</given-names></name></person-group>. <article-title>Estimating odds ratios through the connected comparative experiments</article-title>. <source>Commun Stat Theory Meth</source> <year>1999</year>; <volume>28</volume>(<issue>3-4</issue>): <fpage>905</fpage>–<lpage>929</lpage>.</citation></ref>
<ref id="bibr14-0962280211432220"><label>14</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Senn</surname><given-names>SJ</given-names></name></person-group>. <article-title>'Equivalence is different' - Some comments on therapeutic equivalence</article-title>. <source>Biometr J</source> <year>2005</year>; <volume>47</volume>(<issue>1</issue>): <fpage>104</fpage>–<lpage>107</lpage>.</citation></ref>
<ref id="bibr15-0962280211432220"><label>15</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Yates</surname><given-names>F</given-names></name></person-group>. <article-title>Incomplete randomized blocks</article-title>. <source>Ann Eugenics</source> <year>1936</year>; <volume>7</volume>: <fpage>121</fpage>–<lpage>140</lpage>.</citation></ref>
<ref id="bibr16-0962280211432220"><label>16</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Yates</surname><given-names>F</given-names></name></person-group>. <article-title>A new method for arranging variety trials involving a large number of varieties</article-title>. <source>J Agricult Sci</source> <year>1936</year>; <volume>26</volume>: <fpage>424</fpage>–<lpage>455</lpage>.</citation></ref>
<ref id="bibr17-0962280211432220"><label>17</label><citation citation-type="book"><person-group person-group-type="author"><name><surname>Hinkelmann</surname><given-names>K</given-names></name><name><surname>Kempthorne</surname><given-names>O</given-names></name></person-group>. <source>Design and analysis of experiments: advanced experimental design</source>, <publisher-loc>Hobokken</publisher-loc>: <publisher-name>Wiley</publisher-name>, <year>2005</year>.</citation></ref>
<ref id="bibr18-0962280211432220"><label>18</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Yates</surname><given-names>F</given-names></name></person-group>. <article-title>The recovery of inter-block information in variety trials arranged in three-dimensional lattices</article-title>. <source>Ann Eugenics</source> <year>1939</year>; <volume>9</volume>: <fpage>136</fpage>–<lpage>156</lpage>.</citation></ref>
<ref id="bibr19-0962280211432220"><label>19</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Aitken</surname><given-names>AC</given-names></name></person-group>. <article-title>On least-squares and linear combinations of observations</article-title>. <source>Proc Roy Soc Edinburgh</source> <year>1934</year>; <volume>55</volume>: <fpage>42</fpage>–<lpage>48</lpage>.</citation></ref>
<ref id="bibr20-0962280211432220"><label>20</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Senn</surname><given-names>S</given-names></name></person-group>. <article-title>Hans van Houwelingen and the art of summing up</article-title>. <source>Biometr J</source> <year>2010</year>; <volume>52</volume>(<issue>1</issue>): <fpage>85</fpage>–<lpage>94</lpage>.</citation></ref>
<ref id="bibr21-0962280211432220"><label>21</label><citation citation-type="other"><comment>International Conference on Harmonisation. ICH harmonised tripartite guideline: choice of control group and related issues in clinical trials. In: <italic>International Conference on Harmonisation</italic>, 20 July 2000</comment>.</citation></ref>
<ref id="bibr22-0962280211432220"><label>22</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Farkouh</surname><given-names>ME</given-names></name><name><surname>Kirshner</surname><given-names>H</given-names></name><name><surname>Harrington</surname><given-names>RA</given-names></name><name><surname>Ruland</surname><given-names>S</given-names></name><name><surname>Verheugt</surname><given-names>FW</given-names></name><name><surname>Schnitzer</surname><given-names>TJ</given-names></name><etal/></person-group>. <article-title>Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), cardiovascular outcomes: randomised controlled trial</article-title>. <source>Lancet</source> <year>2004</year>; <volume>364</volume>(<issue>9435</issue>): <fpage>675</fpage>–<lpage>684</lpage>.</citation></ref>
<ref id="bibr23-0962280211432220"><label>23</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Schnitzer</surname><given-names>TJ</given-names></name><name><surname>Burmester</surname><given-names>GR</given-names></name><name><surname>Mysler</surname><given-names>E</given-names></name><name><surname>Hochberg</surname><given-names>MC</given-names></name><name><surname>Doherty</surname><given-names>M</given-names></name><name><surname>Ehrsam</surname><given-names>E</given-names></name><etal/></person-group>. <article-title>Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), reduction in ulcer complications: randomised controlled trial</article-title>. <source>Lancet</source> <year>2004</year>; <volume>364</volume>(<issue>9435</issue>): <fpage>665</fpage>–<lpage>674</lpage>.</citation></ref>
<ref id="bibr24-0962280211432220"><label>24</label><citation citation-type="other"><comment>Senn S. Lessons from TGN1412 and TARGET: implications for observational studies and meta-analysis. <italic>Pharm Stat</italic> 2008; <bold>7</bold>(4): 294–301</comment>.</citation></ref>
<ref id="bibr25-0962280211432220"><label>25</label><citation citation-type="book"><person-group person-group-type="author"><name><surname>Hsu</surname><given-names>JC</given-names></name></person-group>. <source>Multiple comparisons theory and methods</source>, <publisher-loc>Boca Raton</publisher-loc>: <publisher-name>Chapman &amp; Hall/CRC</publisher-name>, <year>1996</year>.</citation></ref>
<ref id="bibr26-0962280211432220"><label>26</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hsu</surname><given-names>JC</given-names></name><name><surname>Peruggia</surname></name></person-group>. <article-title>Graphical representations of Tukey's multiple comparison method</article-title>. <source>J Comput Graph Stat</source> <year>1994</year>; <volume>3</volume>: <fpage>143</fpage>–<lpage>146</lpage>.</citation></ref>
<ref id="bibr27-0962280211432220"><label>27</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Fisher</surname><given-names>RA</given-names></name></person-group>. <article-title>Contribution to a discussion of J. Neyman's paper on statistical problems in agricultural experimentation</article-title>. <source>J Roy Stat Soc</source> <year>1935</year>; <volume>2</volume>: <fpage>154</fpage>–<lpage>157</lpage>.</citation></ref>
<ref id="bibr28-0962280211432220"><label>28</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Senn</surname><given-names>SJ</given-names></name></person-group>. <article-title>Added values: Controversies concerning randomization and additivity in clinical trials</article-title>. <source>Stat Med</source> <year>2004</year>; <volume>23</volume>(<issue>24</issue>): <fpage>3729</fpage>–<lpage>3753</lpage>.</citation></ref>
<ref id="bibr29-0962280211432220"><label>29</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Senn</surname><given-names>SJ</given-names></name></person-group>. <article-title>The many modes of meta</article-title>. <source>Drug Inform J</source> <year>2000</year>; <volume>34</volume>: <fpage>535</fpage>–<lpage>549</lpage>.</citation></ref>
<ref id="bibr30-0962280211432220"><label>30</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ruhkin</surname><given-names>A</given-names></name></person-group>. <article-title>Two procedures of meta-analysis in clinical trials and interlaboratory studies</article-title>. <source>Tatra Mountains Math Publ</source> <year>2003</year>; <volume>26</volume>: <fpage>155</fpage>–<lpage>168</lpage>.</citation></ref>
<ref id="bibr31-0962280211432220"><label>31</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>DerSimonian</surname><given-names>R</given-names></name><name><surname>Laird</surname><given-names>N</given-names></name></person-group>. <article-title>Random-effects model for meta-analysis of clinical trials: an update</article-title>. <source>Contemp Clin Trials</source> <year>2007</year>; <volume>28</volume>: <fpage>105</fpage>–<lpage>114</lpage>.</citation></ref>
<ref id="bibr32-0962280211432220"><label>32</label><citation citation-type="book"><person-group person-group-type="author"><name><surname>McCullagh</surname><given-names>P</given-names></name><name><surname>Nelder</surname><given-names>JA</given-names></name></person-group>. <source>Generalized linear models</source>, <edition>2nd edn</edition>. <publisher-loc>London</publisher-loc>: <publisher-name>Chapman and Hall</publisher-name>, <year>1989</year>.</citation></ref>
<ref id="bibr33-0962280211432220"><label>33</label><citation citation-type="book"><person-group person-group-type="author"><name><surname>Senn</surname><given-names>SJ</given-names></name></person-group>. <source>Statistical issues in drug development</source>, <edition>2nd edn</edition>. <publisher-loc>Hoboken</publisher-loc>: <publisher-name>Wiley</publisher-name>, <year>2007</year>.</citation></ref>
<ref id="bibr34-0962280211432220"><label>34</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Senn</surname><given-names>SJ</given-names></name></person-group>. <article-title>Trying to be precise about vagueness</article-title>. <source>Stat Med</source> <year>2007</year>; <volume>26</volume>: <fpage>1417</fpage>–<lpage>1430</lpage>.</citation></ref>
<ref id="bibr35-0962280211432220"><label>35</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hoaglin</surname><given-names>DC</given-names></name><name><surname>Hawkins</surname><given-names>N</given-names></name><name><surname>Jansen</surname><given-names>JP</given-names></name><name><surname>Scott</surname><given-names>DA</given-names></name><name><surname>Itzler</surname><given-names>R</given-names></name><name><surname>Cappelleri</surname><given-names>JC</given-names></name><etal/></person-group>. <article-title>Conducting indirect-treatment-comparison and network-meta-analysis studies: report of the ISPOR Task Force on Indirect Treatment Comparisons Good Research Practices: part 2</article-title>. <source>Value Health</source> <year>2011</year>; <volume>14</volume>(<issue>4</issue>): <fpage>429</fpage>–<lpage>437</lpage>.</citation></ref>
<ref id="bibr36-0962280211432220"><label>36</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Thompson</surname><given-names>SG</given-names></name></person-group>. <article-title>Systematic review - why sources of heterogeneity in metaanalysis should be investigated</article-title>. <source>Br Med J</source> <year>1994</year>; <volume>309</volume>(<issue>6965</issue>): <fpage>1351</fpage>–<lpage>1355</lpage>.</citation></ref>
<ref id="bibr37-0962280211432220"><label>37</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Feige</surname><given-names>G</given-names></name><name><surname>Leutert</surname><given-names>T</given-names></name><name><surname>De Pover</surname><given-names>A</given-names></name></person-group>. <article-title>Na,K-ATPase isozymes in rat tissues: differential sensitivities to sodium, vanadate and dihydroouabain</article-title>. <source>Prog Clin Biol Res</source> <year>1988</year>; <volume>268B</volume>: <fpage>377</fpage>–<lpage>384</lpage>.</citation></ref>
<ref id="bibr38-0962280211432220"><label>38</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hermansen</surname><given-names>K</given-names></name><name><surname>Kipnes</surname><given-names>M</given-names></name><name><surname>Luo</surname><given-names>E</given-names></name><name><surname>Fanurik</surname><given-names>D</given-names></name><name><surname>Khatami</surname><given-names>H</given-names></name><name><surname>Stein</surname><given-names>P</given-names></name></person-group>. <article-title>Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin</article-title>. <source>Diab Obes Metabol</source> <year>2007</year>; <volume>9</volume>(<issue>5</issue>): <fpage>733</fpage>–<lpage>745</lpage>.</citation></ref>
<ref id="bibr39-0962280211432220"><label>39</label><citation citation-type="book"><person-group person-group-type="author"><name><surname>Royall</surname><given-names>R</given-names></name></person-group> <article-title>The likelihood paradigm for statistical evidence</article-title>. In: <person-group person-group-type="editor"><name><surname>Taper</surname><given-names>ML</given-names></name><name><surname>Lele</surname><given-names>SR</given-names></name></person-group> (eds). <source>The nature of scientific evidence</source>, <publisher-loc>Chicago</publisher-loc>: <publisher-name>University of Chicago Press</publisher-name>, <year>2004</year>, pp. <fpage>119</fpage>–<lpage>138</lpage>.</citation></ref>
<ref id="bibr40-0962280211432220"><label>40</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Julious</surname><given-names>S</given-names></name><name><surname>Wang</surname><given-names>SJ</given-names></name></person-group>. <article-title>How biased are indirect comparisons, particularly when comparisons are made over time in controlled trials</article-title>. <source>Drug Inform J</source> <year>2008</year>; <volume>42</volume>(<issue>6</issue>): <fpage>625</fpage>–<lpage>633</lpage>.</citation></ref>
<ref id="bibr41-0962280211432220"><label>41</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Chapell</surname><given-names>R</given-names></name><name><surname>Gould</surname><given-names>AL</given-names></name><name><surname>Alexander</surname><given-names>CM</given-names></name></person-group>. <article-title>Baseline differences in A1C explain apparent differences in efficacy of sitagliptin, rosiglitazone and pioglitazone</article-title>. <source>Diab Obes Metab</source> <year>2009</year>; <volume>11</volume>(<issue>11</issue>): <fpage>1009</fpage>–<lpage>1016</lpage>.</citation></ref>
</ref-list>
<app-group><app id="app1-0962280211432220"><title>Appendix</title>
<sec id="sec8-0962280211432220"><title/>
<p>
<table-wrap id="table3-0962280211432220" position="float"><label>Table A1.</label><caption><p>Table of statistics used for analysis. Each row is an arm. Study identifier and treatments are given as well as number of patients treated, mean score and standard deviation. The comment column indicates whether the figures are based on raw values at outcome or change from baseline</p></caption><graphic alternate-form-of="table3-0962280211432220" xlink:href="10.1177_0962280211432220-table3.tif"/>
<table frame="hsides" rules="groups"><thead align="left">
<tr><th>Study</th><th><italic>n</italic></th><th>Treatment</th><th>Comment</th><th>mean_final</th><th>SD_final</th>
</tr></thead>
<tbody align="left">
<tr>
<td>De Fronzo (1995)</td>
<td>213</td>
<td>metformin</td>
<td>Change</td>
<td>−1.700</td>
<td>1.459</td>
</tr>
<tr>
<td>De Fronzo (1995)</td>
<td>209</td>
<td>placebo</td>
<td>Change</td>
<td>0.200</td>
<td>1.446</td>
</tr>
<tr>
<td> Lewin (2007)</td>
<td>431</td>
<td>metformin</td>
<td>Change</td>
<td>−0.740</td>
<td>1.106</td>
</tr>
<tr>
<td> Lewin (2007)</td>
<td>144</td>
<td>placebo</td>
<td>Change</td>
<td>0.080</td>
<td>1.004</td>
</tr>
<tr>
<td> Willms (1999)</td>
<td>29</td>
<td>metformin</td>
<td>Change</td>
<td>−2.500</td>
<td>0.862</td>
</tr>
<tr>
<td> Willms (1999)</td>
<td>31</td>
<td>acarbose</td>
<td>Change</td>
<td>−2.300</td>
<td>1.782</td>
</tr>
<tr>
<td> Willms (1999)</td>
<td>29</td>
<td>placebo</td>
<td>Change</td>
<td>−1.300</td>
<td>1.831</td>
</tr>
<tr>
<td> Davidson (2007)</td>
<td>117</td>
<td>rosiglitazone</td>
<td>Change</td>
<td>−1.200</td>
<td>1.097</td>
</tr>
<tr>
<td> Davidson (2007)</td>
<td>116</td>
<td>placebo</td>
<td>Change</td>
<td>0.140</td>
<td>1.093</td>
</tr>
<tr>
<td>Wolffenbuttel (1999)</td>
<td>183</td>
<td>rosiglitazone</td>
<td>Change</td>
<td>−0.900</td>
<td>1.100</td>
</tr>
<tr>
<td>Wolffenbuttel (1999)</td>
<td>192</td>
<td>placebo</td>
<td>Change</td>
<td>0.200</td>
<td>1.110</td>
</tr>
<tr>
<td> Kipnes (2001)</td>
<td>182</td>
<td>pioglitazone</td>
<td>Change</td>
<td>−1.200</td>
<td>1.369</td>
</tr>
<tr>
<td> Kipnes (2001)</td>
<td>181</td>
<td>placebo</td>
<td>Change</td>
<td>0.100</td>
<td>1.024</td>
</tr>
<tr>
<td> Kerenyi (2004)</td>
<td>160</td>
<td>rosiglitazone</td>
<td>Change</td>
<td>−0.910</td>
<td>0.990</td>
</tr>
<tr>
<td> Kerenyi (2004)</td>
<td>154</td>
<td>placebo</td>
<td>Change</td>
<td>−0.140</td>
<td>0.920</td>
</tr>
<tr>
<td> Hanefeld (2004)</td>
<td>319</td>
<td>pioglitazone</td>
<td>Raw</td>
<td>7.610</td>
<td>1.072</td>
</tr>
<tr>
<td> Hanefeld (2004)</td>
<td>320</td>
<td>metformin</td>
<td>Raw</td>
<td>7.450</td>
<td>1.073</td>
</tr>
<tr>
<td> Derosa (2004)</td>
<td>45</td>
<td>pioglitazone</td>
<td>Raw</td>
<td>6.800</td>
<td>0.800</td>
</tr>
<tr>
<td> Derosa (2004)</td>
<td>42</td>
<td>rosiglitazone</td>
<td>Raw</td>
<td>6.700</td>
<td>0.900</td>
</tr>
<tr>
<td> Baksi (2004)</td>
<td>218</td>
<td>rosiglitazone</td>
<td>Change</td>
<td>−1.200</td>
<td>1.112</td>
</tr>
<tr>
<td> Baksi (2004)</td>
<td>233</td>
<td>placebo</td>
<td>Change</td>
<td>0.100</td>
<td>1.036</td>
</tr>
<tr>
<td>Rosenstock (2008)</td>
<td>59</td>
<td>rosiglitazone</td>
<td>Change</td>
<td>−1.170</td>
<td>1.229</td>
</tr>
<tr>
<td>Rosenstock (2008)</td>
<td>57</td>
<td>placebo</td>
<td>Change</td>
<td>−0.080</td>
<td>1.208</td>
</tr>
<tr>
<td> Zhu (2003)</td>
<td>210</td>
<td>rosiglitazone</td>
<td>Change</td>
<td>−1.900</td>
<td>1.470</td>
</tr>
<tr>
<td> Zhu (2003)</td>
<td>105</td>
<td>placebo</td>
<td>Change</td>
<td>−0.400</td>
<td>1.300</td>
</tr>
<tr>
<td> Yang (2003)</td>
<td>102</td>
<td>rosiglitazone</td>
<td>Change</td>
<td>−1.090</td>
<td>1.650</td>
</tr>
<tr>
<td> Yang (2003)</td>
<td>96</td>
<td>metformin</td>
<td>Change</td>
<td>−0.950</td>
<td>1.500</td>
</tr>
<tr>
<td>Vongthavaravat (2002)</td>
<td>164</td>
<td>rosiglitazone</td>
<td>Change</td>
<td>−1.100</td>
<td>1.559</td>
</tr>
<tr>
<td>Vongthavaravat (2002)</td>
<td>170</td>
<td>SUalone</td>
<td>Change</td>
<td>0.100</td>
<td>0.992</td>
</tr>
<tr>
<td> Oyama (2008)</td>
<td>41</td>
<td>acarbose</td>
<td>Change</td>
<td>−0.700</td>
<td>0.800</td>
</tr>
<tr>
<td> Oyama (2008)</td>
<td>43</td>
<td>SUalone</td>
<td>Change</td>
<td>−0.300</td>
<td>0.600</td>
</tr>
<tr>
<td> Costa (1997)</td>
<td>36</td>
<td>acarbose</td>
<td>Change</td>
<td>−1.100</td>
<td>0.360</td>
</tr>
<tr>
<td> Costa (1997)</td>
<td>29</td>
<td>placebo</td>
<td>Change</td>
<td>−0.300</td>
<td>0.700</td>
</tr>
<tr>
<td>Hermansen (2007)</td>
<td>106</td>
<td>sitagliptin</td>
<td>Change</td>
<td>−0.300</td>
<td>0.940</td>
</tr>
<tr>
<td>Hermansen (2007)</td>
<td>106</td>
<td>placebo</td>
<td>Change</td>
<td>0.270</td>
<td>0.940</td>
</tr>
<tr>
<td> Garber (2008)</td>
<td>132</td>
<td>vildagliptin</td>
<td>Change</td>
<td>−0.630</td>
<td>1.034</td>
</tr>
<tr>
<td> Garber (2008)</td>
<td>144</td>
<td>placebo</td>
<td>Change</td>
<td>0.070</td>
<td>1.080</td>
</tr>
<tr>
<td> Alex (1998)</td>
<td>291</td>
<td>metformin</td>
<td>Change</td>
<td>0.130</td>
<td>1.428</td>
</tr>
<tr>
<td> Alex (1998)</td>
<td>300</td>
<td>SUalone</td>
<td>Change</td>
<td>0.500</td>
<td>1.450</td>
</tr>
<tr>
<td> Johnston (1994)</td>
<td>68</td>
<td>miglitol</td>
<td>Change</td>
<td>−0.410</td>
<td>1.072</td>
</tr>
<tr>
<td> Johnston (1994)</td>
<td>63</td>
<td>placebo</td>
<td>Change</td>
<td>0.330</td>
<td>1.032</td>
</tr>
<tr>
<td> Johnston (1998a)</td>
<td>91</td>
<td>miglitol</td>
<td>Change</td>
<td>−0.430</td>
<td>0.954</td>
</tr>
<tr>
<td> Johnston (1998a)</td>
<td>43</td>
<td>placebo</td>
<td>Change</td>
<td>0.980</td>
<td>1.311</td>
</tr>
<tr>
<td> Kim (2007)</td>
<td>57</td>
<td>rosiglitazone</td>
<td>Change</td>
<td>−1.100</td>
<td>1.341</td>
</tr>
<tr>
<td> Kim (2007)</td>
<td>56</td>
<td>metformin</td>
<td>Change</td>
<td>−1.100</td>
<td>1.139</td>
</tr>
<tr>
<td> Johnston (1998b)</td>
<td>49</td>
<td>miglitol</td>
<td>Change</td>
<td>−0.120</td>
<td>1.400</td>
</tr>
<tr>
<td> Johnston (1998b)</td>
<td>34</td>
<td>placebo</td>
<td>Change</td>
<td>0.560</td>
<td>1.166</td>
</tr>
<tr>
<td>Gonzalez-Ortiz (2004)</td>
<td>34</td>
<td>metformin</td>
<td>Change</td>
<td>−1.300</td>
<td>1.861</td>
</tr>
<tr>
<td>Gonzalez-Ortiz (2004)</td>
<td>37</td>
<td>placebo</td>
<td>Change</td>
<td>−0.900</td>
<td>1.803</td>
</tr>
<tr>
<td> Stucci (1996)</td>
<td>28</td>
<td>benfluorex</td>
<td>Raw</td>
<td>8.030</td>
<td>1.290</td>
</tr>
<tr>
<td> Stucci (1996)</td>
<td>30</td>
<td>placebo</td>
<td>Raw</td>
<td>8.260</td>
<td>1.350</td>
</tr>
<tr>
<td> Moulin (2006)</td>
<td>161</td>
<td>benfluorex</td>
<td>Change</td>
<td>−0.820</td>
<td>1.028</td>
</tr>
<tr>
<td> Moulin (2006)</td>
<td>156</td>
<td>placebo</td>
<td>Change</td>
<td>0.190</td>
<td>1.374</td>
</tr>
</tbody>
</table>
</table-wrap>
</p>
</sec></app></app-group></back>
</article>